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The aim of this project was to develop [Co(µ-OH)2Pt] prodrugs that can undergo bio-
reduction in hypoxic cells within solid tumours. This thesis describes synthetic methods to 
produce heterodinuclear [Co(µ-OH)2Pt] complexes. Purification methods and 
characterisation of this class of complexes are also discussed.  
The formation of [{Co(µ-OH)nM}m] complexes (M = transition metals) by  reaction between 
equilibrium mixtures of cis- and trans-[Co(en)2(OH)(OH2)]
2+ and different metal ions was 
studied using 13C NMR spectroscopy, in order to gain a better understanding of the 
reactions that may be occurring in solution. This involved monitoring the effect of the added 
metal ions on the position of the cis-trans equilibrium of the Co complex. This work is 
described in chapter 2. 
In chapter 3, the synthesis and characterisation of [Co(µ-OH)2Pt] complexes is discussed. 
Formation of [Co(µ-OH)2Pt] complexes has been confirmed, following separations on ion 
exchange resins. These complexes proved to be rather labile and this led to insurmountable 
difficulties when attempting to isolate these complexes in pure form.   
Problems associated with purification of [(en)2Co(µ-OH)Pt(L)] and [(tren)Co(µ-OH)Pt(L)] (L = 
chda, (NH3)2) complexes led us to synthesise a new class of [Co(µ-OH)2Pt] complexes, 
bearing a nitrilotriacetate ligand, as many reported anticancer drugs in literature are neutral 
(chapter 4). Both characterisation and biological assessment of these complexes was 
hindered by their low solubility. However, NMR studies at high temperature in DMSO again 
demonstrated the lability of these complexes. 
In summary, [Co(µ-OH)2Pt] complexes can be made, but they proved to be very labile and 
they do decompose. The direction of this research should be changed in future in order to 
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produce a less labile [Co(µ-OH)2Pt] system. We speculate that this may be possible by 
incorporating a bulky group to reduce ligand exchange on platinum. 
In chapter 5, a conclusion for synthesis of dinuclear [Co(µ-OH)2Pt] complexes and the future 
work for this study are discussed. 
Chapter 6 describes the synthesis and characterisation of organotin complexes which can be 
potential anticancer drugs. 

























Cancer is a class of diseases characterised by out-of-control cell growth. In 2012, the New 
Zealand Cancer Registry received 21,814 new cancer registrations. This was a rate of 337.5 
new cases of cancer per 100,000 people[1]. There are over 100 different types of cancer, and 
each is classified by the type of cell that is initially affected[2]. All cancers begin in cells. The 
human body is made up of more than a hundred billion cells. Cancer starts with changes in 
one cell or a small group of cells. Cells produce signals to control how much and how often 
the cells divide. If any of these signals are faulty or missing, a cell and its daughters may start 
to grow and multiply too often and form a lump or mass called a tumour (except in the case 
of leukaemia where cancer prohibits normal blood function by abnormal cell division in the 
blood stream). The place where the cancer starts is called the primary tumour. 
Tumours can grow and interfere with the digestive, nervous and circulatory systems and they 
can release hormones altering body function. Tumours that stay in one spot and 
demonstrate limited growth are generally considered to be benign. More dangerous, or 
malignant, tumours form when two conditions occur: 
1. A cancerous cell manages to spread throughout the body using the blood or lymph 
systems, destroying healthy tissues in a process called invasion. 
2. A cancerous cell divides and grows in a new location, making new blood vessels to feed 
itself in a process called angiogenesis. 
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 Once a tumour successfully spreads to other parts of the body and grows, invading and 
destroying other healthy tissues, it is said to have metastasised. This process itself is called 
metastasis, and the result is a serious condition which is very difficult to treat[3]. 
 
1.2 Chemotherapy 
Chemotherapy works by stopping or slowing the growth of cancer cells, which grow and 
divide quickly. Many of these treatments target rapidly dividing cells (not necessarily just 
cancer cells), but normal cells usually can recover from any chemical-induced damage while 
cancer cells cannot. Chemotherapy is generally used to treat cancer that has spread or 
metastasised, because the medicines travel throughout the entire body. It is a necessary 
treatment for some forms of leukaemia and lymphoma[4]. 
 Chemotherapy treatment often occurs in cycles, so the body has time to heal between 
doses. Chemotherapy treatment uses medicine to weaken and destroy cancer cells in the 
body, including cells at the original cancer site and any cancer cells that may have spread to 
another part of the body. Chemotherapy medicines prevent cancer cells from growing and 
spreading by destroying the cells or stopping them from dividing[5]. 
Due to the rapid proliferation of cancer cells, sometimes they break away from the original 
tumour and travel to other places in the body. Chemotherapy weakens and destroys cancer 
cells at the original tumour site and throughout the body. 
Normal cells usually grow and divide in a precise, orderly way. However, some normal cells 
do divide quickly, including cells in hair follicles, nails, the mouth, digestive tract, and bone 
marrow (bone marrow makes blood cells). Chemotherapy also can unintentionally harm 
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these other types of rapidly dividing cells, possibly causing chemotherapy side effects. This 
unintentional targeting of non-cancerous cells leads to side effects such as hair loss, nausea, 
fatigue, and vomiting. Combination therapies often include multiple types of chemotherapy 
or chemotherapy combined with other treatment options[5]. 
 
 Classes of Chemotherapy Drugs 1.1.1
1.1.1.1 Alkylating Agents 
The oldest class of anticancer drugs are alkylating, nitrogen mustard compounds, showing 
remarkable chemotherapeutic activity in cancer treatment. Nitrogen mustard compounds 
are poisonous and initially developed for military purpose.   
Nitrogen mustard compounds attack at the nucleophilic centre of DNA, mainly the guanine 
N7 and O6[6]. Alkylation of the DNA, leads to DNA strand breaks and DNA strand cross-
linking, which stops the cellular activity and the cell will die.  
1.1.1.2 Antimetabolites 
 
The first effective chemotherapeutic agents based on antimetabolite drugs are folic acid, 
pyrimidine or purine analogues. They are characterised by low molecular weights. They 
have similar structures as naturally occurring molecules used in nucleic acid (DNA and RNA) 
synthesis. Antimetabolites are similar to chemicals needed for normal biochemical activity, 
but differ enough so that they interfere with normal cell function. Generally, 
antimetabolites induce cell death during the S phase of cell growth when incorporated into 
RNA and DNA or inhibit enzymes needed for nucleic acid production. These agents are used 
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Anthracyclines work by the formation of oxygen free radicals. These oxygen free radicals 
lead to breaking of DNA strands and this inhibits DNA synthesis and function. The enzyme 
topoisomerase is also inhibited as a complex is formed by the enzyme and DNA. Many of the 
effective anti-cancer drugs in this class come from natural products.  
1.1.1.4 Taxanes 
Another class of chemotherapeutics are the taxanes, these are specific for the M phase of 
the cell cycle. They bind to microtubules and inhibit their normal function. This class of 
drugs has a broad range of applications in cancer treatment.  
1.1.1.5 Platinum agents 
Platinum agents operate by DNA cross-linking. The cross-link inhibits DNA synthesis, 
transcription and function. The platinum compounds are not cell cycle specific. The most 
important platinum drugs bare a large similarity to cisplatin because of its high anti-cancer 
activity.  
 
1.3 Cisplatin, the first platinum anticancer drug 
Cis-diamminedichloridoplatinum or cisplatin (cis-[PtCl2(NH3)2]) was the first inorganic cancer 
chemotherapeutic agent (Figure 1-1). It was first prepared by an Italian chemist Michele 
Peyrone, a Professor of Chemistry at the University of Genoa, in 1845 [7] . This compound, 
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originally known as ‘Peyrone’s chloride’, was of fundamental interest in the development of 
the ‘coordination theory’, for which Alfred Werner earned the Nobel Prize in 1913. 
 
 
Figure  1-1. Structure of the antitumour drug, cisplatin(1.1), and its inactive trans isomer, 
transplatin(1.2) 
 
In the mid-1960s, Barnett Rosenberg and his co-workers serendipitously discovered that 
cisplatin exhibited antitumour activity, whereas the trans isomer, trans-[PtCl2(NH3)2] did not 
[8]. In 1972, cis-[PtCl2(NH3)2] was first tested in clinical trials in human patients 
[9]. Cisplatin is 
active against a wide spectrum of solid neoplasms, including ovarian, testicular, bladder, 
colorectal, lung and head and neck cancers[10],[11]. It was approved by the U.S. Food and Drug 
Administration as an anti-cancer treatment in 1979 [12]. Currently, cis-[PtCl2(NH3)2] is one of 
the most widely used anti-cancer agents.  
The drug often leads to an initial therapeutic response associated with complete disease 
remission, partial response or disease stabilisation. However, cisplatin therapy requires 
additional medication and is accompanied by severe side effects including dose-limiting 
nephrotoxicity (renal toxicity), ototoxicity (ear poisoning) due to irreversible damage of the 
hair cells in Corti organ, myelosuppression (bone marrow suppression) as well as nausea 
and vomiting.  
These toxic side effects limit the therapeutic efficacy of cisplatin [13],[14],[15]. In addition to the 
serious side effects, inherent or treatment-induced resistant tumour cell sub-populations 
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also restrict the therapeutic efficacy of cisplatin[16],[17]. These toxic side effects of cisplatin 
limit the dose that can be administered to patients. 
 
1.4 New platinum drugs 
 
Due to the fact that cis-[PtCl2(NH3)2] exhibits severe renal toxicity and has narrow 
applicability to a few tumour types, the search has continued for less toxic and a wider 
variety of platinum-containing anti-cancer agents. Consequently, new platinum complexes 
such as carboplatin, nedaplatin, oxaliplatin (Figure 1-2), and thousands of other platinum 
compounds have been synthesised and studied for clinical usage [18].  
The toxicity of cisplatin can be decreased by exchanging the labile chloride ligands for 
comparatively more stable bidentate leaving groups, thereby slowing down the hydrolytic 
activation of the drugs[19]. The diaqua form of cisplatin is highly toxic, and that toxicity can 
possibly be decreased by reducing the lability of the leaving ligand, while more stable 
bidentate leaving ligands can still produce active complexes, and activity is only lost when 
very tightly bound ligands are used[20]. Once the chloride leaving groups are substituted by 
more stable ligands, such as 1,1-cyclobutanedicarboxylate, the renal effects are decreased, 
while the antitumour activity remains[21]. Three of the “second-generation” platinum drugs, 
fulfilling the requirements mentioned above, are currently used in cancer chemotherapy: 
carboplatin, nedaplatin and oxaliplatin, Figure 1-2[19]. 
 





Figure  1-2 Structures of clinically used antitumour drugs:  carboplatin (1.3), nedaplatin (1.4) and 
oxaliplatin (1.5) 
 
Carboplatin, the most successful complex of these second-generation platinum 
complexes[22], and nedaplatin[23] are cisplatin derivatives that show less nephrotoxicity, 
gastrointestinal toxicity, neurotoxicity and vomiting[22],[23],[24],[25]. Carboplatin has achieved 
worldwide approval and steadily increasing acceptance as a less toxic alternative to 
cisplatin, while nedaplatin has received only limited approval[19]. Oxaliplatin exhibits a safe 
toxicity profile, and in various clinical situations is superior to cisplatin by being less toxic 
and retaining activity against cisplatin-resistant tumours [26], [27], [28]. 
 
1.5 Mechanism of Cisplatin Antitumour Activity 
 
The most recent review of the mechanism of cisplatin was discussed as follows[29],[30]. The 
mechanism of action of cisplatin and the classical platinum drugs analogous to cisplatin are 
very similar. Compounds analogous to cisplatin are complexes that are neutral, square-
planar including two cis amine and two cis anionic ligands[31]. The amine groups which can 
be chelating or non-chelating ligands are referred to as non-leaving groups because they 
stay bound to the Pt metal centre throughout the course of intercellular transformation. In 
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contrast, the leaving groups which can be monodentate or chelating ligands leave the Pt 
coordination sphere. 
The general mechanism of action contains four key steps: 1) cellular uptake 2) aquation or 
activation of the Pt drugs, 3) DNA interaction, and 4) cellular processing of DNA lesions 
leading to the cell death[31].  
There are different cellular events which appear to contribute to the cytotoxic effect of 
cisplatin, although binding of platinum to DNA is found as a crucial step. Drug resistance can 
be generated by abnormality in any of the following effects. The mechanisms of cisplatin 
resistance have been classified as pre-target (i.e., those interfering with cisplatin transport 
prior to DNA binding), on-target (repair of Pt-DNA lesions), post-target (cellular events 
taking place after DNA platination) and off-target (alterations in signalling pathways not 
directly engaged by cisplatin but interfering with cisplatin induced proapoptotic events)[32]. 
Before any reaction can take place between cisplatin and DNA, the platinum drug must 
enter the cell. However, cisplatin is vulnerable to attack by proteins found in blood plasma, 
particularly those that contain thiol groups, such as human serum albumin. The cisplatin 
that remains intact can enter tumour cells; previously it was believed to be mainly by 
diffusing through the cell membrane because of the concentration dependence of cisplatin 
[33],[34],[35]. Recent studies demonstrate that the copper transporter 1 (CTR1) plays an 
important role in the uptake of cisplatin as well as other ATPase’s extrude copper[36]. Active 
transport mediated by membrane proteins is the predominant mechanism of action. For 
instance, cisplatin efficacy has been linked to the level of expression of the copper 
transporters[37],[38],[39]. In a similar way, oxaliplatin uptake has been linked to expression of 
organic cation transporters[40]. 
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The square-planar geometry of cisplatin facilitates ligand substitution which is the crucial 
step for formation of DNA lesions. Cisplatin undergoes a ligand substitution even prior to 
DNA binding in which a chloride ligand is replaced by a water molecule. This aquation is 
more likely to occur in the cytoplasm, where the chloride ion concentration drops below 20 
mM[41]. In the presence of these lower salt concentrations vs bloodstream (~100 mM), the 
half-life of the aquation reaction, producing cis-[Pt(NH3)2Cl(H2O)]
+, is approximately 2 h. The 
positively charged aquated cisplatin can enter the nucleus, and can be substituted by DNA 
bases. 
The ultimate target for cisplatin inside the cell is DNA. Platinum ions react preferably with 
nitrogen atom donors in ligands rather than O atoms. In fact, the preferred binding site in 
DNA is the N7 atom of purines nucleobases[42],[43],[44],[45],. At physiological pH, the N3 atom of 
thymine is protonated, while the N3 of purines are sterically hindered[45] and aromatic 
nitrogen atoms without a σ lone pair are not available for platinum coordination. The N1 of 
adenine and the N3 atom of cytosine are appropriate positions for platinum binding. The 
potential platinum binding sites on DNA bases are represented with arrows in Figure 1-3.  




Figure  1-3 Available binding sites for platinum. Guanine-N(7) is the preferred site for initial binding 
of the platinum(II) complex, since guanine is the most nucleophilic DNA base  
 
All four presented positions can be coordinated to platinum, but the preferred binding site 
is the N7 atom of guanine, showing a strong kinetic preference[46],[43]. This tendency results 
from the strong basicity of that position, and from hydrogen bonding interactions between 
amine protons of cisplatin with O6 in guanine and their accessibility for the platinum 
complexes[47]. 
In vitro studies have shown that this monoaquated platinum species is responsible for at 
least 98% of the platinum binding to DNA within the cell nucleus[48]. Cisplatin reacts with 
one of the DNA bases, usually guanine, forming a monofunctional DNA adduct  [48-49], [50]. 
Ring closure to form a bifunctional adduct may occur either directly from the 
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monofunctional adduct or may involve aquation of the second chloride ligand followed by 
rapid ring closure [51], [52].  
The reaction of cisplatin with DNA results in the formation of six major categories of Pt-DNA 
adducts. The most important ones are schematically depicted in Figure 1-4. The major 
adduct formed by cisplatin, was found to be the 1,2-intrastrand d(GpG) cross-links on 
adjacent purine bases, followed by 1,2-intrastrand d(ApG)[53] cross-links between an 
adjacent adenine and guanine, 1,3-intrastrand d(GXG) and 1,4-intrastrand d(GXXG) cross-
links between purines separated by one or two intervening bases, respectively.  
A small percentage of cisplatin was found to be involved in interstrand cross-links, linking 
the two strands of the DNA double helix, or in monofunctional adducts coordinated to a 
single purine and protein-DNA cross-link, in which cisplatin coordinates a protein molecule 




Figure  1-4 Main adducts formed in the interaction of cisplatin with DNA. (a) interstrand cross-link; 
(b) 1,2-intrastrand cross-link; (c) 1,3-intrastrand cross-link; (d) protein-DNA cross-link[55] 
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Cisplatin-DNA adducts result in distortion of the DNA that can be recognised by one or more 
DNA binding proteins. These proteins can either initiate a DNA damage repair (Figure 1-5, 
path b) or signal for apoptosis (cell death) to be initiated (Figure 1-5, path a) [51], [52], [56], [57].  
























Figure  1-5 Schematic depiction of the cytotoxic pathway for cisplatin. After entering the cell, 
cisplatin is aquated, and then binds to cellular DNA. If the DNA lesion is not repaired by the cell (path 
a), then cell death (apoptosis) can occur [48]. 
 
 
1.6  Tumour Microenvironment 
 
Solid tumours are associated with multiple cell types and altered extracellular 
matrix[58],[59],[60],[61]. The abnormal architecture of tumours leads to a unique 
microenvironment which is different from normal tissue[60],[62]. One major difference 
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between many solid tumours and surrounding normal tissue is the nutritional and metabolic 
environment. 
 The functional vasculature of tumours is often insufficient to supply the nutritional needs of 
the expanding population of tumour cells, resulting in deficiency of oxygen and many other 
nutrients. Hydrolysis of adenosine triphosphate (ATP) in an energy-deficient environment 
under anaerobic metabolism  produces lactic acid [63]. The protons generated by this 
process, are not subsequently consumed by ATP re-synthesis, and instead accumulated in 
the extracellular space[64]. 
Wike-Hooley and his colleagues have provided a complete review of several thousand 
microelectrode measurements of pH in human and animal tumours[65]. Their results are 
summarised as follows: determination of pH in subcutaneous tissue and muscle ranged 
from 7.00 to 8.06, with mean values of 7.52 for human subcutaneous tissue, and 7.32 and 
7.43 for muscle in dogs and rats, respectively. There is a wider range of pH values in 
malignant tissue, from about 5.8 to 7.6 in both human and rodent tumours. There is 
considerable variation within different regions of the same tumour but in general; tumours 
are more acidic than normal tissues with median pH values of about 7.0 in tumours and 7.5 
in normal tissues. 
Accumulative distributions of pH obtained in tumours and normal tissues by Wike-Hooley 
and his colleagues are presented in Figure 1-6[65]. 
 








1.7 Tumour hypoxia 
 
Tissue oxygen levels are not uniformly distributed in the same organ. Levels of oxygenation 
depend on diffusion of oxygen from blood vessels and the distance from a functional blood 
vessel; therefore distant areas from blood vessels are more hypoxic [66],[67].  
Human solid tumours are invariably less well-oxygenated than the normal tissues. Due to 
the aggressive proliferation of tumour cells, oxygen demand is high in tumours. In addition, 
disorganised blood vessel formation in tumours makes blood flow sluggish, and therefore 
oxygen supply can be lower in some parts of the tumour[68],[69]. Moreover, the tightly packed 
interface between tumour cells prevents oxygen diffusion to the inside of tumour tissue 
[69],[62]. 
Most solid tumours contain hypoxic regions. Hypoxic cells are relatively resistant to 
radiotherapy[70] and chemotherapy[71] due to the low concentration of oxygen. Often the 
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proliferation rate in hypoxic tumour cells is lower than normoxic cells, limiting the impacts 
of anticancer drugs which target the cell cycle and/or rapid proliferating cells. Thus, efficient 
delivery of drugs to hypoxic regions of solid tumours is another consideration in the 
chemotherapeutic treatment of cancer[62]. 
There are at least three potential reasons why cells, which are distant from blood vessels, 
might be resistant to chemotherapy: first, most anticancer drugs exert selective toxicity on 
cycling cells, so that non proliferating or slowly proliferating cells are resistant[72]; second, 
some drugs might be less active in hypoxic, acidic or nutrient deprived 
microenvironments[73],[63]; and third, cells distant from blood vessels might be exposed to 
low concentrations of the drug due to its limited access. 
Diffusion of fluorescent Pt-based compounds into multicellular tumour spheroids has 
demonstrated that the outer layers of the spheroid receive or accumulate very much higher 
doses of drug than the central cells[74]. This has little effect on the population of hypoxic 
cells in the central part of the spheroid that potentially do not receive an adequate dose of 
the anticancer drug. 
Traditional hypoxia-activated prodrugs (based on nitroimidazoles, quinones, or aromatic N-
oxides) rely on reoxidation of the active form to the inert form in normal cells, but not in 
cancer cells[75]. Healthy tissues, however, can also be highly hypoxic under certain 
conditions. Thus to completely avoid toxic side effects, it is essential for prodrugs to have 
high activation thresholds[76]. Cobalt(III) complexes can have their redox potential fine-tuned 
by ligand choice to coincide with the cytoplasmic environment in cancer cells rather than 
normal cells[77]. Thus such agents offer a feasible route to develop selective prodrugs. 
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1.8 Application of cobalt complexes in hypoxia selectivity 
 
As detailed in the previous section, hypoxic cells limit the response of tumours to radiation 
therapy[78],[79] and perhaps chemotherapy[73]. Hypoxia, however, can be turned into an 
advantage for selective cancer therapy because it is much more severe in tumours than in 
normal tissues[76],[80]. 
Prodrugs are inert agents that can be activated by external stimulation such as light, ionising 
radiation, or reducing environments[81]. Due to resistance of hypoxic cancer cells to 
conventional radiotherapy and chemotherapy, hypoxia-activated prodrugs are highly 
sought-after. 
Bioreductive activation is a process by which an inert agent undergoes reduction upon cell 
entry, releasing one or more bioactive agents (Figure 1-7)[82]. Cobalt(III) complexes are 
relatively inert and usually adopt octahedral geometries and, owing to the high crystal field 
stabilisation energy of Cobalt (III) (d6, low spin). Co(II) complexes (d7, high-spin) on the other 
hand are more labile and susceptible to ligand substitution[77]. The active Co(II) form is 
thought to undergo re-oxidation back to the inert Co(III) form in normoxic cells[77]. 
Cobalt(III) prodrugs can potentially be converted to an active form through the intracellular 
reduction by xanthine and NADPH oxidase, or cytochrome P450[83],[84],[85]. Co(II) can be 
reoxidised to the parent prodrug by the molecular oxygen present in normal tissues, but in 










Figure  1-7 The proposed mechanism of action for Co(III) prodrugs in a hypoxic region. Co(III) 
complexes are hypothesised to undergo a bio-reduction within the hypoxic region in solid tumours. 




1.9 Cobalt(III)-mustard agents 
 
Nitrogen mustard agents are a class of clinically approved anticancer chemotherapy 
drugs,[87] that induce their therapeutic effect by alkylating purine DNA bases[88]. The 
mechanism of action of nitrogen mustards for alkylating DNA is shown in Figure 1-8. 
Using a hypoxia activated Co(III) inert metal centre, is one of the strategies to target their 
cytotoxicity. This is achieved by complexing the Co(III) metal centre to the nitrogen 
mustards[89]. Coordination of the nitrogen lone pair of the nitrogen mustard to Co(III) can 
supress its toxicity due to the fact that the electron pair is no longer available to activate the 
nitrogen mustard by making an aziridinum ion. Co(III) complexes are kinetically inert[90]. The 
nitrogen mustard ligand can then be released by reduction of Co(III) to labile Co(II). The 
cytotoxic nitrogen mustard might be released by rapid ligand exchange with surrounding 
water molecules. 




Figure  1-8  A mechanism of nitrogen mustards for the alkylation of DNA 
 
 
The ancillary ligands present on the Co(III) metal centre are important to tune the 
physiologically and chemically important properties of the complex such as Co(III)/Co(II) 
reduction potential, overall charge, solubility and lipophilicity. These factors play a major 
role for entry of the prodrug into the biological system and also release of the active 
nitrogen mustard to the target sites. 
Co(III) complexes containing amine and nitrido ligands are very effective radiation 
sensitisers for hypoxic mammary carcinoma cells (EMT6)[91]. Among Co(III)-nitrido  
complexes, those containing acetylacetonate (acac) and nitrogen mustard ligands, such as 
bis(2-chloroethyl)amine, were especially effective against cultured murine tumour cells[92] 
(Figure 1-9).  
 




Figure  1-9 Structures of hypoxia activated Co(III) prodrugs with monodentate and bidentate nitrogen 
mustard ligands 
 
Compound 1.6 (Figure 1-9) in its oxidised state is inert, and the nitrogen lone pair of the BCA 
component is involved in coordination to cobalt and unavailable for intramolecular 
formation of an aziridinium ion, which is a perquisite for DNA alkylation. In the reduced 
state, BCA released from the resulting Co(II) complex, produces a cytotoxic effect. 
Cytotoxicity studies showed that 1.6 displays strong radio-sensitisation of hypoxic mammary 
carcinoma cells (EMT6) and exhibited higher toxicity towards oxygenated cells than hypoxic 
cells[92]. 
The Ware research group used the same rational design employed for compound 1.6 to 
develop Co(III)–nitrido complexes with alkylating aziridine groups, to release the bioactive 
ligands under hypoxic conditions[93]. Unfortunately, testing of complexes in a hypoxic cell 
culture indicated that the complexes underwent facile reduction, leading to uncontrolled 
release of the aziridine groups. Bidentate mustard ligands, BCE and DCE, were used to 
synthesise a new class of Co(III)–acetylacetonate complexes (1.7-9 and 1.10–12). Biological 
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results from these complexes revealed that metal complexes of nitrogen mustards have 
significant hypoxia-selective cytotoxicity toward mammalian cells in cell culture, and are a 
new series of hypoxia-selective cytotoxins[94],[90],[95]. 
Matching the cytotoxicity trend of the Co(III)-BCE and Co(III)-DCE complexes with the free 
mustard agents, implied that the toxicity was due to the release of the mustard agents. 
Complex 1.8, was 6-fold more cytotoxic towards Chinese hamster ovary fibroblast cells (AA8 
and UV4) grown in hypoxic conditions than the same cells cultured in aerobic conditions[87]. 
This complex also exhibited high activity against mammary carcinoma cells (EMT6) in intact 
spheroids. Spheroids have hypoxic centres, therefore 1.8 induced toxicity is believed to be 
caused by DCE release within the core followed by back-diffusion to the outer areas[94]. 
Structure activity relationship studies found that the nature of the ancillary ligand, 
acetylacetonate, was crucial to hypoxic selectivity. While Co(III)-DCE complexes with 
unsubstituted acetylacetonate displayed no hypoxic selectivity, methyl and ethyl analogues 
showed considerable selectivity[94]. 
Replacement of acetylacetonate with bis-troplonate yielded complexes that are structurally 
similar to related complexes with acac ancillary ligands (Figure 1-10). Tropolonates are flat 
molecules when they coordinated to the Co(III) centre. Formation of complexes of this kind 
with bulky tertiary amine nitrogen mustard ligands can minimise the steric hinderance.  
 The tropolonato complexes have significantly higher reduction potentials than the 
corresponding acac complexes due to their electron withdrawing nature[96]. The tropolonato 
ligands therefore facilitate the cellular reduction of the coordinated Co(III) centres and 
accordingly release of the mustard ligand. 




Figure  1-10 Chemical structure of bis-tropolonato dervatives of Co(III) as potential hypoxia selective 
cytotoxins 
 
Biological results showed that complexes 1.13 and 1.15, have cytotoxicity similar to the free 
mustard in cell culture under oxic and hypoxic conditions. For this reason, unsubstituted bis-
tropolonate was deemed to be an unsuitable ancillary ligand for generating hypoxic 
selective Co(III) complexes. The two non-mustard complexes, 1.14 and 1.16, where the 
ligands are incapable of forming DNA adducts, showed much lower AA8/UV4 IC50 ratios. 
The ancillary ligands present on the Co(III) centre are also important to tune the 
physiologically and chemically important properties of the complex such as Co(III) to Co(II) 
reduction potential, overall charge, solubility and hydrophilicity or lipophilicity. These 
factors play a major role for entering the prodrug into the biological system and also in 
releasing the active nitrogen mustard into the target sites.  
In order to develop physiologically stable Co(III)-prodrugs with enhanced hypoxic selectivity, 
tridentate mustard agents were synthesised (Figure  1-11)[89]. Introducing electron 
withdrawing groups into the tropolone ring could generate hypoxia-selective complexes. 
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Replacement of acetylacetonate with carbonato and oxalato ligands afforded Co(III)-DCE 
complexes (1.17 and 1.18) with reasonable hypoxic selectivity (2–4-fold against UV4 cells) 
(Figure 1-11)[97]. Nevertheless, the hypoxic selectivity of 1.8 was still superior to that of 1.17 
and 1.18 under the same conditions. 
 
Figure  1-11 Hypoxia active Co(III) prodrugs 
 
Co(III)–acetylacetonate complexes containing DCD (1.19) proved to be much less cytotoxic 
than the corresponding bidentate analogue DCE used previously. The reason for this is not 
known; while both would be expected to have similar chemical reactivity, the tridentate 
analogue DCD may have slower kinetics of cell uptake. However, both had similar AA8/UV4 
IC50 ratios (19- vs. 26-fold), suggesting that DNA crosslinking is the major mode of 




1.10 Cobalt(III) complexes as carrier for bioactive ligands 
New approaches to cancer therapy have involved the selective inhibition of enzymes 
involved in the process of tumour metastasis. The development of potent inhibitors of these 
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enzymes has resulted in a new class of drugs that have antimetastatic and cytostatic 
action[98].  
One such therapy involves combating the action of specific matrix metalloproteinases 
(MMPs). Hambley and co-workers utilised the electrochemical properties of Co(III) 
complexes to selectively deliver matrix metalloproteinase (MMP) inhibitors to target 
tumour sites[99]. MMPs are a family of zinc-dependent peptidases which have been 
implicated in cancer progression and other diseases[99]. 
MMPs decompose the extracellular matrix (ECM) of cancer cells in primary tumour sites, 
providing cancer cell migration and metastasis[100]. Despite the fact that several exogenous 
MMP inhibitors have been developed to restrain metastasis in cancer patients, none have 
been clinically approved (the only FDA-approved MMP inhibitor is doxycycline (Figure 1-12), 
which is used as a periodontitis (gum disease) treatment)[101]. 
 
 
Figure  1-12 Structure of doxycycline 
 
 A major deficiency in the structural design of some of the MMP inhibitors developed to 
date (like marimastat and batimastat (Figure 1-13) is the exposed hydroxamate acid group.  




Figure  1-13 Marimastat and Batimastat chemical structure 
 
Indeed, the poor oral bioavailability of these inhibitors in clinical trials is thought to result 
from non-specific reactions between the hydroxamate acid group and biomolecules[102]. 
Hambley’s research group linked MMP inhibitors to Co(III)-TPA via the hydroxamate acid 
moiety (Figure 1-14) to overcome this problem [99].  
The result was deactivation of the MMP inhibitors in normoxic sites, and selective release in 
hypoxic regions (upon reduction of the inert Co(III) complex to the more reactive Co(II) 
complex).  
Initial electrochemical studies with prototypical systems containing simple alkyl and aryl 
hydroxamate acid ligands (1.23-25), established that Co(III)-TPA was a suitable transporter 
of hydroxamate acid-containing compounds to hypoxic sites[103]. Having obtained these 
results, marimastat, a potent MMP inhibitor, was attached to Co(III)-TPA via the two oxygen 
atoms on the hydroxamate acid moiety (1.26) (Figure 1-14).  




Figure  1-14 Chemical structure of Co(III)-TPA with different hydroxamate acid ligands 
 
 
Complex 1.26 suppressed 4T1.2 tumour growth in mice more effectively than free 
marimastat. This was tentatively attributed to the failure of primary tumours in the control 
group to reach an appropriate size[99]. In light of this seemingly conflicting in vivo data, the 
authors suggested that further experiments with longer administration times were needed 
to calculate the true efficacy of 1.26. More recent studies involving Co(III)-TPA complexes, 
1.23-125 showed that both the hydroxamate and hydroximate forms (Figure 1-15) could be 
isolated[104]. 
 
Figure  1-15 Hydroxamate and hydroximate acid structures 
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 The reduction potential of the two protonated states was notably different, and thus the 
ability of the complexes to release the bound ligand was also different. The differing 
electrochemical properties of the hydroxamate and hydroximate forms could be modified to 
develop Co(III) systems capable of delivering bioactive ligands (containing hydroxamate 
acids) to acidic regions. 
Other tetradentate ligand systems, aside from TPA have also been used to prepare Co(III) 
carriers for biologically active ligands (Figure 1-17). Ware et al. showed that Co(III)-1,4,7,10-
tetraazacyclododecane (cyclen) complexes were effective carriers for cytotoxins such as 8-
hydroxyquinoline (8-HQ) and azaCBI[83],[105],[106]. Detailed mechanistic studies revealed that 
these systems (1.27 and 1.28) underwent efficient reduction (and cytotoxin release) in 
hypoxic cells through radiolytic and non-radiolytic pathways, upon exposure to ionising 
radiation. Moreover, 1.28 displayed selective potency (20-fold) towards colorectal 
adenocarcinoma cells (HT29) grown in hypoxic conditions over the same cells cultured in 
oxic conditions[83]. Systematic modification of the azaCBI backbone yielded analogues with 
greater hypoxic selectivity[107].  
To improve solubility and stability, 1,7-substituted cyclen ligands containing anionic 
sulfonato, phosphinato and carboxylato groups were employed (1.30, 1.31 and 1.32)[108]. 
Biological studies of 1.30, 1.31, 1.32, 1.33, 1.34 and 1.35, demonstrated that although 
solubility was slightly improved, their stability (in cell culture media) and hypoxic selectivity 
were commensurate to the parent complexes (1.28 and 1.28) 
 




Figure  1-16 Chemical structures of Co(III) carriers with tetradentate ligand systems 
 
Larger macrocyclic ligands such as 1,4,8,11-tetraazacyclotetradecane (cyclam), with cross-
bridged nitrogen atoms have  been used as well (1.36 and 1.37)[109]. The bridging of 
opposing nitrogen atoms within cyclam was proposed to force the nitrogen lone pairs to 
align better with the cobalt d-orbitals, preorganising the host site and ensuring formation of 
only complexes with cis geometry. This potentially allows a better fit around the Co(III) 
centre, thereby stabilising Co(III) relative to Co(II) and lowering the reduction potential of 
the Co(III) complexes. The most effective complex in this series, 1.36, showed 81–212-fold 
higher toxicity under hypoxia than 20% oxygen against a panel of human cancer cell 
lines[109]. Interestingly, the cytotoxicity of this complex was not increased in cell lines 
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overexpressing reduction which is known as a initiator of other hypoxia-activated prodrugs 
(based on nitroaromatics and quinones)[110]. A similar trend was observed for the cyclen 
bearing derivative, 1.28. Given these results, the identity of the reductase or non-enzymatic 
reductant reducing these complexes, remains unknown. There is speculation that the 
lipophilicity of these complexes facilitates mitochondrial accumulation, resulting in 
reduction by the mitochondrial electron transport chain[83]. However, there is no 
experimental evidence for this mechanism reported. 
 
1.11 Thesis Coverage 
 
As mentioned in earlier sections, Lack of discrimination between cancer cells and normal 
tissue is the main problem of cytotoxic anti-cancer drugs. Commonly, anti-cancer drugs act 
on cells that divide rapidly, one of the main properties of cancer cells. Therefore, damage 
can be expected in particular in rapidly dividing normal cells, like bone marrow, 
gastrointestinal mucosa and hair follicles. This results in the most common side effects of 
chemotherapy like myelosuppression (decreased production of blood cells), mucositis 
(inflammation of the lining of the digestive tract) and alopecia (hair loss) [111]. 
Another problem in cancer therapy is the existence of hypoxia in solid tumours and that low 
oxygenation can accelerate malignant progression and metastasis, thereby creating a poorer 
prognosis irrespective of which cancer treatment is used[112]. 
The presence of hypoxic cells in human tumours provides an important target for selective 
cancer therapy. The main goal of this project is to synthesise smart targeted drug delivery 
systems that deliver drugs to cancer cells with better efficacy and lower toxicity levels. 
Therefore, we are going to develop synthetic routes to achieve novel heterodinuclear  
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[Co(µ-OH)2Pt] complexes. This will be done within the context of developing an entirely new 
approach to delivering platinum anti-cancer drugs to targeted sites in the body. 
The Co(III) ion is kinetically inert, that is, it exchanges ligands only very slowly, but when 
reduced to Co(II) (by bioreduction after entering to hypoxic cells) the ligands will be 
exchanged rapidly. This results in release of the platinum component which will be an anti-
cancer drug.   
In chapter 2, the formation of [{Co(µ-OH)nM}m] complexes ((M= metal ion) by reaction 
between equilibrium mixtures of cis- and trans-[Co(en)2(OH)(OH2)]
2+ and different metal 
ions is studied  using 13C NMR spectroscopy, in order to gain a better understanding of the 
reactions that may be occurring in solution.  
In chapter 3, the synthesis, characterisation and purification of dinuclear [Co(µ-OH)2Pt] 
complexes are discussed. 
In chapter 4, the synthesis and characterisation of a new class of dinuclear [Co(µ-OH)2Pt] 
complexes bearing a nitrilotriacetate (nta) ligand are discussed. The scope of this chapter is 
to produce neutral [Co(µ-OH)2Pt] complexes in order to facilitate the isolation of the 
dinuclear complexes.  
In chapter 5, the conclusion and future prospects of this research are discussed. 
In chapter 6, the syntheses and characterisation of organotin complexes with pttp and ottp 
ligands (Figure 1-17) are explained. 
In chapter 7, the experimental work relevant to this thesis is described in detail. 
 






































Exploring Formation of Dinuclear 















Syntheses of [{Co(µ-OH)nM}m] complexes (M= transition metals) have been studied 
previously[113],[114],[115],[116] and the products have been characterised by X-ray 
crystallography and spectroscopically. Here we summarise the structures of some    
dinuclear and polynuclear [{Co(µ-OH)nM}m] type complexes. 
In 1888, Jørgensen reported the synthesis of a compound containing a cation which he 
described as being dinuclear[117]. In 1907, Werner provided the final piece of evidence of his 
theory of octahedral coordination by demonstrating the optical activity of species 
containing bidentate inorganic “ligands” for the cluster cations of composition 
[Co{(OH)2Co(NH3)4}3]
6+ (Figure 2-1)[118]. Alfred Werner was awarded the Nobel Prize in 1913 
for coordination theory. 
 
 






Another complex, believed by Werner to be a hexol (Werner’s supposed hexol,  Figure 2-2), 
was synthesised  by Jackson et al [119] according to Werner’s procedure [118],[120] but the 1H 
NMR study did not agree with Werner’s original formulation. The expected singlet for the 18 
equivalent NH3 protons, and another singlet for the six equivalent OH protons at very high 
field (well above SiMe4), were not observed. Instead, a lower symmetry complex was 
apparent, but one clearly bearing the high field bridging OH protons. 
 
 
Figure  2-2. The structure proposed by Werner for his second hexol 
The product was purified by ion-exchange chromatography and the single crystal X-ray 
structural analysis was performed on a crystal which proved to be a double salt of 
composition [NH4]2[Co6(NH3)14(OH)8(O)2](ZnCl4)2 ]. The complex cation is shown in Figure 2-
3. 
 
Figure  2-3. The structure of Werner’s second hexol 
 
Tetranuclear complexes with the general formula of [MII((OH)2M
IIIA4)3]
5+ (where MII is Mg, 




two bidentate ethane-1,2-diamine (en) ligands, or one tetradentate N,N'-bis(2-
methylpyridyl)propane-l,3-diamine (bispictn) ligand) have similar structures to each 
other[113]. The inner coordination spheres around the metal centres in the 
[Co{(OH)2Cr(bispictn)}3]
5+ cation are depicted in Figure 2-4. 
 
 




X-ray diffraction studies showed that metal ions such as Mn3+, Ni2+, Zn2+ and Mg2+ bind to 
[(en)2Co(H2O)2]
2+ to give the structure shown in Figure 2-5 a. The complexes of the form 
[{(en)2Co(µ-OH)2}2M(H2O)2]
3+ containing Cu2+and Co2+ metal ions have the structure 
illustrated in Figure 2-5 b[115]. The complexes containing Pd2+ and Pt2+ metal ions have the 







Figure  2-5 Structures of the Co complex [(en)2Co(H2O)2]
3+) in association with a) Mn3+, Ni2+, Zn2+, 
Mg2+ [121] b) Cu2+, Co2+  [115], c) Pd2+ and Pt2+ metal ions[116] 
 
This chapter examines the formation of products of this kind in the solution state. [Co(µ-
OH)n-M] (M= metal ions) heterodinuclear (and polynuclear) complexes were synthesised via 
reaction between [Co(en)2(OH)(OH2)](ClO4)2 and different metal ions (M= Zn
2+, Mg2+, Ni2+, 
Cu2+, Co2+, Mn3+, Pd2+ and Pt2+). 
 
2.2 Using NMR spectroscopic techniques to explore dinuclear complex formation in 
solution 
 
The complexes described above, were studied in the solid state by X-ray crystallography, but 
the nature of the chemistry that occurs in solution may be different. It is important to 
explore how the chemistry in solution relates to the data from the solid state. NMR 
spectroscopy is the best technique to study the behaviour of such systems in solution, at 
least for diamagnetic metal ions, and under some circumstances for paramagnetic metal 
ions.  
The progress of reactions which will be explained in the following part, were monitored by 
13C NMR spectroscopy. Before dealing into any detail, there are certain details that are 




that 13C is only present as 1.1 % of the total carbon content of any organic compound. This, 
in combination with an inherently less sensitive nucleus, means that signal to noise issues 
will always be a major consideration in the acquisition of 13C spectra. So it takes a great deal 
longer to acquire 13C NMR spectra than it does 1H NMR spectra.  
Another important aspect of 13C NMR spectroscopy is that the signals are not normally 
integrated. The reason for this is that some carbon signals have quite long relaxation times. 
In order to make NMR signals quantitative, and therefore more suitable for integration, 
acquisition must allow for a relaxation delay (delay period between acquisition pulses) of at 
least five times the duration of the slowest relaxing nuclei in the compound being 
considered. However, on the assumption that chemically similar carbon atoms have similar 
relaxation times, reasonably reliable integrations can be obtained without such long delays 
being necessary.  
The standard is usually added directly to the NMR solvent and is thus referred to as an 
internal standard. It is also possible to insert a small tube containing standard in solvent into 
the bulk of the sample so that the standard does not come into direct contact with the 
sample. This would be referred to as an external standard. We used an internal standard in 
our research for reasons of convenience. In the present research, the usage of an internal 
standard helped to follow changes in chemical shifts. In some cases, an internal standard 
was used to compare the integration of a signal with the internal standard’s integration and 





2.3 Data analysis 
 
13C NMR was used to monitor the formation of [(en)2Co(µ-OH)n-M] (M = Zn
2+, Mg2+, Ni2+, 
Cu2+, Co2+, Mn3+, Pd2+ and Pt2+) complexes. The reaction progress was monitored by 13C NMR 
spectroscopy. TMPS was used as an internal standard when diamagnetic metal ions were 
present.  
Experimental data could be conveniently presented by plotting graphs of cis to trans ratio vs 
molar equivalent and chemical shift vs molar equivalent. The cis to trans ratio was obtained 
by addition of the integrations of the two cis signals and dividing by the integration of the 
trans signal. 
For the cis to trans ratio vs molar equivalent graphs, the standard error for each signal 
integration was calculated using the equations presented in Appendix 1, and error bars 
were drawn. In cases where the cis signals were broadened through interactions with 
paramagnetic metal ions, dioxane was added as an internal standard to allow absolute 
integration of the remaining signal.  
In some cases, the standard errors associated with a data point were too small to be 
plotted. 
 
2.4 Results and Discussion 
 
The 13C-NMR spectrum of [Co(en)2(OH)(OH2)](ClO4)2  in D2O contains three signals at 46.19, 
46.98 and 47.71 ppm with relative integrations of 0.68, 1 and 0.70 at 25° C (Figure 2-6).  
Results from isotopic analysis described in the literature show that the cis and trans isomers 




for formation of the equilibrium is approximately 3 minutes for this facile cis-trans 
isomerisation[122],[123] . 
 
Figure  2-6. The 13C NMR spectrum of [Co(en)2(OH)(OH2)]




Figure  2-7. Cis to trans facile isomerisation of [Co(en)2(OH)(OH2)]
2+ 
 
There are two kinds of carbon atoms in the cis isomer but when it converts to the trans 
isomer, there is only one kind of carbon atom (Figure 2-7). Therefore, it is expected to see 
two signals for cis-[Co(en)2(OH)(OH2)]
2+ and one signal for its trans isomer. Consequently, 




the cis isomer and the single signal at 46.9 ppm to the trans- isomer. The cis to trans ratio 
can be obtained by adding the integrations of the two cis signals together and dividing by 
the integration of the trans signal. The cis to trans ratio value for [Co(en)2(OH)(OH2)]
2+ under 
our conditions is 1.4.  
Apart from cis and trans peaks in 13C NMR spectra, some small peaks were observed at 
longer reactions times which may be related to deuterium exchange. Deuterium isotope 
exchange on the amine group has already reported[124]. Deuterium isotope exchange results 
in having -CH2-NH2, -CH2-NHD, and -CH2-ND2 in the NMR sample. As a result, small signals 
appear next to main signals. Two closely spaced signals in the 13C NMR spectrum might be 
assigned to the carbon atoms affected by deuterium isotope exchange on their neighboring 
amine group. 
 
2.4.1 Studies with diamagnetic metal ions 
NMR titrations of [Co(en)2(OH)(OH2)](ClO4)2 with different metal ions were analysed in order 
to find out the interaction between them in the solution state and also to find out the 
progress of the reaction. Each titration was carried out inside a NMR tube, with 
[Co(en)2(OH)(OH2)](ClO4)2 (0.0860 g, 1 eq) and different molar equivalents of M (M= Li(NO3), 
K(NO3), Mg(NO3)2, Ag(NO3), Zn(ClO4)2,  Zn(NO3)2, Cd(NO3)2, K2[PdCl4] and K2[PtCl4]) in 1 ml 
D2O).  TMPS (3-(trimethylsilyl)-1-propane-sulfonic acid) was added inside the tube as an 
internal reference. The 13C-NMR spectrum was taken at least 30 minutes (>10 t1/2) after 
addition of the metal ion to the cobalt complex solution. 
The 13C NMR spectra of [Co(en)2(OH)(OH2)]
2+ were taken after addition of 0.1, 0.3, 0.5, 1, 2, 




ratio and chemical shifts. In addition, different peak heights can be seen compared to those 
seen in Figure 2-7. The cis peak height increased while the trans peak height decreased. The 
spectra presented here are those obtained with 0.5, 1 and 2 equivalents of Zn2+ (Figure 2-8), 
and should be compared to Figure 2-6. 
The value of the cis to trans ratio changed from 1.370.00 to 5.020.00 after addition of 
0.50 equivalents of Zn2+. This shows that the cis isomers are becoming more stable than the 
trans- isomer as Zn2+ is added. In addition, there is an alteration of chemical shift of about 
0.29 ppm for the cis(A) signal relative to cis(A) in Figure 2-7, which is significant in 
comparison to the changes of 0.05 ppm for cis(B) and 0.03 ppm for the trans signal. These 
spectral changes can be understood using the equilibria presented in Figure 2-9. The 
changes in cis to trans ratio imply that Kc is significantly larger than Kt. Having had one set of 
signals for each isomer in Figure 2-9, may suggest the fast addition and loss of Zn2+ species 





Figure  2-8 a) The 13C NMR spectrum of [Co(en)2(OH)(OH2)]
2+ after addition of 0.5 equivalent Zn2+ in 
D2O in presence of TMPS internal standard b) The
 13C NMR spectrum of [Co(en)2(OH)(OH2)]
2+ after 
addition of 1 equivalent Zn2+ in D2O in presence of TMPS internal standard c) The
 13C NMR spectrum 
of [Co(en)2(OH)(OH2)]








Figure  2-9  Reaction scheme for [Co(en)2(OH)(OH2)]
2+ with zinc metal ions. 
K1=[B]/[A], Kc=[C]/[A] and Kt=[D]/[B] 
 
Although, the two cis signals are differently affected by addition of the zinc ion (Figure 2-8), 
this cannot clearly be said which of the carbon atoms might be more affected by 
coordinating to the new metal ion. There are two possible interpretations.  Firstly, it could 
be due to the inductive effect through binding of the hydroxide ligands to the Zn2+ ion. In 
this situation, the carbon atoms (C1) on amines in position trans to the hydroxide ligands 




Alternatively, there is a possibility of hydrogen bonding between hydrogen atoms of the zinc 
complex and the hydrogen atoms on amines in cis positions relative to the hydroxide ligands 
of the cobalt complex possibly mediated by a water molecule as is shown below (Figure 2-
10). In the latter case, the chemical environment of C2 (Figure 2-7) may experience a 
greater effect, which results in chemical shift changes. 
 
 
Figure  2-10. Possible hydrogen bonding between Co(µ-OH)2Zn complex 
 
In a separate experiment, 8 equivalents of Zn2+ were added in one aliquot. Results showed 
that even with a large excess addition of metal ion there was still some trans isomer. The 
value of the cis to trans ratio after a single addition of 8 equivalents of Zn2+ is 14.000.05 
and this value for the sequential addition of Zn2+ is 13.850.10 which is very similar, indeed 
just barely within the experimental error of each other.  After a single addition of 8 
equivalents of Zn2+, the small cis peaks next to the large cis peaks, assigned to deuterium 
exchange, were still observed but they were of lower intensity, which is consistent with 
assignments of those peaks. 
The reaction between [Co(en)2(OH)(OH2)]
2+ and Zn(ClO4)2 was repeated with Zn(NO3)2. Since 




reaction appears to be independent of the anion, at least when the anion is relatively non-
coordinating.  
Similar results were obtained for the Cd(NO3)2
 salt. However, the change in cis:trans ratio for 
Cd2+ is less than Zn2+. Changes in chemical shifts and cis:trans ratio with addition of different 




Graph  2-1  Cis:trans ratio of [Co(en)2(OH)(OH2)]
2+ as a function of added molar equivalents of 

























Graph  2-2 Chemical shift of [Co(en)2(OH)(OH2)]
2+ as a function of added molar equivalents of to Zn2. 
Standard errors on this graph’s data points and the succeeding ones are too small to be plotted. 
Chemical shifts were measured relative TMPS internal standard. 
 
 
Graph  2-3 Chemical shift of [Co(en)2(OH)(OH2)]
2+ as a function of added molar equivalents of Cd2+. 
Chemical shifts were measured relative TMPS internal standard. 
  
The 13C NMR titration was repeated for four other diamagnetic metal ions (using the nitrate 
salts: LiNO3, AgNO3, KNO3 and Mg(NO3)2). Results obtained from 
13C NMR spectra of these 














































significant changes in cis/trans ratio and chemical shifts after addition of Li+, Ag+, K+ and 
Mg2+ metal ions to the Co complex. 
After addition of Li+ very small changes were seen in the 13C NMR spectrum. The ratio of cis 
to trans isomers only changed from 1.320.00 to 1.500.00. Even the addition of a large 
excess did not change the cis to trans ratio. The chemical shift of the cis signals and the 
trans signal were changed equally, about 0.11 ppm as 8 equivalents of Li+ added. 
By addition of K+, very slight changes were seen in the 13C NMR spectrum of cobalt complex. 
The ratio of cis to trans isomers only changed from 1.320.00 to 1.490.01. After addition of 
8 equivalents of K+, chemical shifts of cis(A) and cis(B) were changed equally (0.08), and 
more than the trans signal (0.07).  
Considering chemical shifts, cis to trans ratio and equilibria (Figure 2-9), KC is bigger than Kt 
for these metal ions. However, the difference is not large, so we conclude that these metal 
ions do not change the equilibrium between cis and trans significantly and there is less 







Graph  2-4.  Cis:trans ratio of [Co(en)2(OH)(OH2)]
2+ as a function of molar equivalents of 
Li+/K+/Mg2+/Ag+. The lines joining the data points are merely for clarity 
 
After addition of Mg2+ and Ag+ to [Co(en)2(OH)(OH2)]
2+, the cis to trans ratio value was 
changed from 1.320.01 to 2.540.05 and 1.590.01, respectively. The chemical shift of the 
cis(A) signal for both Mg2+ (0.25 ppm) and Ag+ (0.32 ppm) metal ions was changed more 
than that of Li+ and K+. Mg2+ metal ion has the biggest Kc in comparison with K
+, Li+ and Ag+ 
and it can be said that Mg2+ perturbs the equilibrium more. It might be because  2+  metal 
ions are better Lewis acids than 1+ charged ones. Having said that, among  metal ions with a 
1+  charge, the silver ion changes the equilibrium more than other ions, presumably because 
























Graph  2-5. Chemical shift of [Co(en)2(OH)(OH2)]
2+ as a function of added molar equivalents of Li+. 





Graph  2-6. Chemical shift of [Co(en)2(OH)(OH2)]
2+ as a function of added molar equivalents of K+. 


























































Graph  2-7. Chemical shift of [Co(en)2(OH)(OH2)]
2+ as a function of added molar equivalents of Mg2+. 




Graph  2-8. Chemical shift of [Co(en)2(OH)(OH2)]
2+ as a function of added molar equivalents of Ag+. 
Chemical shifts were measured relative TMPS internal standard 
 
2.4.2 Studies with labile paramagnetic metal ions 
Since the NMR technique can still be usefully applied to solutions containing low 
























































2+ and paramagnetic metal ions Cu2+, Ni2+ and Fe2+ (as their NO3
− 
salts) using 13C NMR spectroscopy.  
The 13C NMR spectrum of [Co(en)2(OH)(OH2)]
2+ and the 13C NMR spectrum of this complex 
after addition of 0.1 equivalents of Cu2+ in the presence of 1,4-dioxane as an internal 
standard are shown in Figure 2-11.  
 
 
Figure  2-11. Top: The 13C NMR spectrum of [Co(en)2(OH)(OH2)]
2+ in D2O with 1,4-dioxane added as 
an internal standard for comparison of chemical shift, set at 66.66 ppm, and to determine chemical 
shifts and for comparison of integrations. Bottom: The 13C NMR spectrum of [Co(en)2(OH)(OH2)]
2+ 






 As shown in Figure 2-11b, after addition of 0.1 equivalents of Cu2+, the cis signals of 
[Co(en)2(OH)(OH2)]
2+ have been significantly broadened, to the point that they are barely 
observable above the baseline. This provides strong evidence of a close association of the 
Cu2+ ions with the cis isomer. It can be said that there must be a rapid exchange, as only a 
small amount of Cu2+ affects all of the cis isomer. Having said that, the trans signal appears 
to be largely unaffected, from which we can infer that little, if any, Cu2+ can be bound to 
trans-[Co(en)2(OH)(OH2)]
2+. 
The results obtained from the 13C NMR spectrum of [Co(en)2(OH)(OH2)]
2+ after successive 




FWHM of trans 
signal 
FWHM of dioxane 
0 5.00 2.153 1.485 
0.1 3.48 2.058 1.249 
0.2 1.32 2.8035 2.120 
0.3 0.59 3.1505 2.818 
 
Table  2-1 The 13C NMR spectral data of [Co(en)2(OH)(OH2)]
2+ after addition of Cu2+ in presence of 
dioxane to determine chemical shifts and allow us to compare integrations. 
 
The presence of the internal standard allows monitoring of the position of the cis to trans 
equilibrium, even though the cis signals could not be integrated, because the amount of the 
cis isomer can be inferred using the integrations of the trans isomer and the internal 
standard before and after addition of the paramagnetic ions. Another expectation was that 
if binding between trans-[Co(en)2(OH)(OH2)]
2+ and paramagnetic metal ions does occur, 




maximum (FWHM) was measured. However, due to the fact that width at the half height of 
trans and dioxane signals change consistently with each other, the possibility of binding to 
the trans isomer cannot be evaluated. 
The integration of the trans to dioxane signal decreased from 5.00 to 0.59 as 0.3 equivalents 
of Cu2+ added. After addition of more than 0.3 equivalents of Cu2+, the signal to noise ratio 
decreased to an extent that integration became impossible. Thus, in order to get a better 
signal to noise ratio we increased the collection time from 10 min to 1 hr. In addition, we 
changed some parameters for the NMR experiment, in an effort to improve the appearance 
of the spectrum.  Relaxation delay and acquisition time were decreased accordingly, from 1 
to 0.5 which enabled us to compare the spectra with earlier spectra.  
Unlike Cu2+, after addition of Ni2+, cis signals were seen in 13C NMR spectrum. This may 
mean that at low addition ratios the Ni2+ ions are square planar and therefore diamagnetic, 
but that addition of more than 0.5 eq might lead to paramagnetic octahedral Ni2+ species 
being present in solution. The progress of the reaction was monitored by the cis to trans 
ratio and also by following the change in chemical shifts (Figures 2-12a and 2-12b).  
The presence of additional signals in Figure 2-12b may be because of the formation of 
different stereoisomers, which will be explained later in the chapter, in the section that 






Figure  2-12. a) The 13C NMR spectrum of [Co(en)2(OH)(OH2)]
2+ in D2O before addition of Ni
2+ in D2O
 in 
presence of 1,4-dioxane  b) The 13C NMR spectrum of [Co(en)2(OH)(OH2)]
2+ after addition of 0.1 
equivalents of Ni2+ in D2O
 in presence of 1,4-dioxane  to determine chemical shifts for comparison of 
integrations. 
 
As illustrated in Figure 2-13 and Graph 2-10, the chemical shift of the cis(A) changed 






Graph  2-9. Cis:trans ratio of [Co(en)2(OH)(OH2)]
2+ as a function of added molar equivalents of Ni2+ . 




Graph  2-10. Chemical shift of [Co(en)2(OH)(OH2)]











































Similar to 13C NMR spectra of [Co(en)2(OH)(OH2)]
2+ with Ni2+, cis signals can be seen after 
addition of Fe3+. Due to having both cis and trans signals, the progress of reaction was 
followed by cis to trans ratio and change in chemical shift. 
 The colour of the reaction mixture changed from red to brownish orange after addition of 
Fe3+. We were not able to take NMR spectra for more than 0.2 equivalents of Fe3+ due to the 
error response of the NMR machine, possibly because of the presence of paramagnetic 
metal ions. Results obtained from addition of 0.1 and 0.2 equivalent Fe3+ are shown below 
(Graph 2-11 and Graph 2-12). 
 
 
Graph  2-11. Cis:trans ratio of [Co(en)2(OH)(OH2)]
2+ as a function of added molar equivalents of Fe3+. 























Graph  2-12. Chemical shift of [Co(en)2(OH)(OH2)]
2+ as a function of added molar equivalents of Fe3+. 
Chemical shifts were measured raltive 1,4-dioxane internal standard 
 
From Graph 2-11 we can see that the cis to trans value increased remarkably from 
1.320.04 to 7.160.07 after addition of 0.2 equivalent of Fe3+. In addition, a significant 
change can be seen for cis(A) and trans signals in Graph 2-12.  These two observations are 
strong enough for us to infer association of Co2+ and Fe3+ through hydroxido bridging 
ligands.  
 
2.4.3 Studies with Pt2+ and Pd2+ metal ions 
 
 
After addition of 0.2 equivalents of K2[PtCl4] to an aqueous solution of [Co(en)2(OH)(OH2)]
2+  
and removal of any resulting precipitate ((Co(µ-OH)2Pt) complex), a small signal appeared at 
39.23 ppm. As more equivalents of Pt2+ were added, the intensity of this signal increased. 
From the chemical shift of the new signal, we suspected loss of ethane-1,2-diamine as Pt2+ 
was added and to confirm this, some ethane-1,2-diamine was added and the intensity of the 


























peaks of the starting material would normally be observed. Figure 2-13 shows the 13C NMR 
spectrum of Co2+ complex after addition of 1 equivalent of the Pt2+ metal ion. 
 
Figure  2-13. The 13C NMR spectrum of [Co(en)2(OH)(OH2)]
2+ solutions after addition of 1 equivalent of 
Pt2+ in D2O in presence of TMPS internal standard. 
 
The reaction between K2[PdCl4] and [Co(en)2(OH)(OH2)]
2+ showed similar results to that of 
Pt2+. As illustrated in Figure 2-14, there are extra signals, similar to those observed in the 
case of Pt2+. According to the intensity of the signals and also the chemical shifts that they 
appear at, they may not be related to the deuterium isotope exchange phenomenon.  
 
Figure  2-14. The 13C NMR spectrum of [Co(en)2(OH)(OH2)]
2+ after addition of 1 equivalent of Pd2+ in 




Addition of K2[PtCl4] or K2[PdCl4] results in the formation of precipitates in solution. To see if 
the obtained powders are the same as the crystals reported in the literature (Figure 2-15) 
[116], X-ray powder diffraction experiments were performed. Results presented in Figure 2-
16 show that the powders are the same as the dinuclear complex, [(en)2Co(µ-OH)2MCl2]
+ (M 
= Pd, Pt), found by X-ray diffraction (Figure 2-15) [116]. 
 
 
Figure  2-15 Structure of [(en)2Co(µ-OH)2PtCl2]




Figure  2-16. Powder diffraction of Co-Pt and Co-Pd complexes compared with calculated powder 
diffraction of the crystal reported in literature (Figure 2-15) [116]. Blue, red and black lines refer to 




If we suppose that a complex with four bridging hydroxide ligands (Figure 2-17) is formed in 
solution, there is the possibility of having several stereoisomers. 
If complexes such as that shown in Figure 2-17 are formed, there might be -, - and 
-configurations for two the cobalt centres and additional signals will be observed in the 
NMR spectra. 
 





In this work, we presented NMR studies of the formation of diamagnetic and paramagnetic 
[{Co(µ-OH)n-M}m] complexes (M=Li, K, Mg, Ag, Cd, Zn, Pt, Pd, Cu, Ni and Fe) in solution. 
The 13C NMR study showed that there is an equilibrium between the cis and trans 
[Co(en)2(OH)(OH2)]
2+ complexes. In the case of diamagnetic metal ions, the equilibrium 
between the cis and trans isomer of the Co complex shifts toward the cis isomer after 
addition of metal ions. In addition, the elimination of cis peaks in the 13C NMR after the 
addition of paramagnetic metal ions, showed the association of metal ions with the cis 
isomer of the Co complex. 
Formation of [Co(µ-OH)2-M] (M=Pd and Pt) complexes have been demonstrated by   X-ray 





2+ complex with Pt2+ and Pd2+ species produces several other complexes 
































Chapter 3. Dinuclear Amine-Cobalt(III)-Platinum(II) Complexes 
3.1 Introduction 
There is not much literature precedent for the synthesis of heterodinuclear cobalt-platinum 
complexes with hydroxido bridging ligands. To our knowledge, the molecule shown in Figure 
3-1 is the only [Co(µ-OH)2Pt] complex reported in the literature. Although this molecule 
does not involve a cisplatin derivative, it does show that such a synthesis should be possible. 
This cobalt-platinum heterodinuclear complex was synthesised via a reaction between 
[(en)2Co(H2O)2](ClO4)3 and K2[PtCl4] 
[121]. As it is shown in Figure 3-1, two metal centres are 




Figure  3-1 The structure of [Cl2Pt(µ-OH)2Co(en)2]




3.2 Results and Discussion  
3.1.1 Dinuclear Cobalt-platinum Complexes 
The aim of this study was to produce novel heterodinuclear Co(III)(µ-OH)Pt(II) metal 







The synthetic route to produce the title complex is presented in Scheme 3-1. (cyclohexane-
1,2-diamine)diiodidoplatinum(II) ([Pt(chda)l2] was treated with silver nitrate for 2 days
[125]. 
The silver iodide precipitate was removed by centrifugation and the supernatant was 
reacted with [Co(en)2(OH)(OH2)]
2+. The reaction mixture was stirred for 3 days.  
 
 
Scheme  3-1 Synthetic route to obtain the [(en)2Co(µ-OH)2Pt(chda)]
3+ complex 
 
The crude compound was purified using cation exchange chromatography on CM Sephadex. 
The column was eluted with NaNO3 solutions. The first band was collected and then 
desalted by using size exclusion column chromatography on Sephadex G10. Ultimately, the 
first band from the CM Sephadex column was isolated as a pink powder. Crystals from the 
first fraction were obtained by vapour diffusion of ethanol into an aqueous solution of the 
complex. They were characterised by NMR and X-ray crystallography. 
X-ray crystallography determined the structure to be [Co(CO3)(en)2](NO3) (3.3) as shown in 
Figure 3-2. This compound crystallises with two formula units in the asymmetric unit. Co(III) 
is octahedrally coordinated to the four N atoms of two en ligands and two O atoms of the 




The packing structure of 3.3 is presented in Figure 3-3. There is hydrogen bonding observed 
between O6 of the carbonate ligand and the hydrogen atom on N4, and between O7 and 
O10 of the nitrate ions and hydrogen atoms on N8 and N3 respectively. 
The bond lengths of H4-O6 and H8-O7 are 2.034(4) and 2.059(4) Å respectively. Selected 
bond lengths and bond angles of 3.3 are shown in Tables 3-1 and 3-2. 
 
 






Selected bond lengths for Co1 [Å] Selected bond lengths for Co2 [Å] 
Co1-O2   1.926(3) Co2-O4   1.919(3) 
Co1-O1   1.935(4) Co2-O5   1.926(4) 
Co1-N3   1.959(4) Co2-N5   1.942(4) 
Co1-N4   1.944(3) Co2-N8   1.948(4) 
Co1-N1   1.970(5) Co2-N6   1.948(4) 
Co1-N2   1.947(4) Co2-N7   1.952(5) 
 







Selected bond angles for Co1 [°] Selected bond angles for Co2 [°] 
O2-Co1-O1         68.85(15) O4-Co2-O5          69.02(15) 
O2-Co1-N3         167.46(18) O4-Co2-N5          91.91(16) 
O2-Co1-N4          92.77(16) O4-Co2-N8          90.77(16) 
O2-Co1-N2          96.98(16) O4-Co2-N6          167.25(17) 
O1-Co1-N1         89.20(17) O4-Co2-N7          96.45(17) 
O2-Co1-N2         96.98(16) O5-Co2-N5          90.72(17) 
O1-Co1-N3         98.68(17) O5-Co2-N8          90.68(18) 
O1-Co1-N4         90.01(18) O5-Co2-N6          98.45(17) 
O1-Co1-N1         90.80(18) O5-Co2-N7          165.23(17) 
O1-Co1-N2         165.57(16) N5-Co2-N6          85.69(17) 
N3-Co1-N1         92.38 N5-Co2-N7          92.47(19) 
N4-Co1-N3         85.72(18) N8-Co2-N5          177.28(18) 
N4-Co1-N1         178.03(16) N8-Co2-N6          91.79(17) 
N4-Co1-N2         93.5(2) N8-Co2-N7          86.75(19) 
N2-Co1-N3         95.54(17) N6-Co2-N7          96.17(18) 
 






Figure  3-3 Hydrogen bonding network within the crystal lattice of the complex 3.3. only the oxygen 
atoms (red) involved in hydrogen bonding are shown. 
 
 
The crystal structure of [Co(CO3)(en)2](NO3)·H2O has been published before
[126]. The 
published crystal structure has a water molecule in the structure while our crystal does not. 









a = 9.407 (2) 
b = 23.121 (4) 
c = 11.604 (2) 
a = 11.3918 (7) 
b = 8.4058 (5) 
c = 23.4969 (12) 
Monoclinic, P21/n 
α = 90 
β = 107.315 (3) 
γ = 90 
Monoclinic, P21/c 
α = 90 
β = 96.826 (5) 
γ = 90 
 
Table  3-3. Crystal data comparison of [Co(CO3)(en)2](NO3).H2O and [Co(CO3)(en)2](NO3) 
 
The 13C NMR data are consistent with the crystal structure (Figure 3-4). The two signals at 
43.87 and 44.87 ppm are assigned to the two kinds of carbon atoms of the en ligands. The 
peak at 166.82 ppm is assigned to the carbon atom of the carbonate ligand. A peak at m/z 
239.05 corresponding to [Co(en)2CO3]
+  was also observed in the mass spectrum. 
 
 
Figure  3-4 The 13C NMR spectrum of 3.3 in D2O 
 
The desired product, [(en)2Co(µ-OH)2Pt(chda)]
3+ (3.2), was the principal component of the 




fraction was desalted by evaporation and then extraction of the complex from the residue 
by methanol. A desalting procedure, using acetone extraction and then size exclusion 
column chromatography on Sephadex G10 ultimately gave the complex product as a red 
slurry. Even after several desalting cycles, some salt remained with the product. This 
prevented obtaining elemental analysis results for the complex.  
The complex was characterised by NMR and mass spectrometry techniques. The isotope 
pattern at m/z 523.07 is a good match with ([M - 2H)]+ (Figure 3-5). It is speculated that the 
ion being detected is [(en)2Co(µ-O)2Pt(chda)]
1+; but clearly deprotonation from other sites 
may be possible. 
 






The 1H and 13C NMR Spectra of complex 3.2 were assigned using COSY and HSQC techniques 
(Figures 3-6, 3-7, 3-8 and 3-9). The integration value for the en ligands on Co vs chda ligand 






Figure  3-6 The 1H NMR spectrum of [(en)2Co(µ-OH)2Pt(chda)]
3+ in D2O. The multiple peaks at 2.7 ppm 





Figure  3-7 1H-1H COSY of [(en)2Co(µ-OH)2Pt(chda)]
3+ in D2O. The blue lines represent the en region 
and the red lines indicate the chda region. 
 
The two peaks at 44.69 and 43.65 ppm are assigned to the two kinds of carbon atoms of the 
en ligands on Co. Due to the use of RR,SS-cyclohexane-1,2-diamine, it is expected that the 
chda ligand configuration to be trans in the complex. The two carbon atoms on the 
cyclohexane ring next to the amine groups have the same absolute configurations. The 
Pt(chda) precursor exists as two enantiomers. Because the Co centre in the final complex 
has three chelate rings, it is also a stereogenic centre (with Δ and Λ configurations), which 
means that there are four stereoisomers – two sets of enantiomeric pairs. And the sets will 
have different spectra from each other, although they may be very similar. There are two 
very close sets of peaks were observed for C1,2 and C3,6 of the cyclohexane ring as well as 




carbon atoms came as one peak, presumably because they are too far from at least one of 
the stereocentres to be affected (probably the Co centre). 
 
 
Figure  3-8 Top: The 13C NMR spectrum of [(en)2Co(µ-OH)2Pt(chda)]
3+ in D2O. Bottom: Enlargement of 
the 13C NMR spectrum of complex 3.2. The small peaks in the en region may be due to the existence 





Figure  3-9 1H-13C HSQC of [(en)2Co(µ-OH)2Pt(chda)]
3+ in D2O. The cross peaks for the impurity 
indicate they are en type carbon atoms and may be related to another isomer of the complex 
 
On one occasion, very few red crystals were obtained on standing (and by slow evaporation) 
of a water/methanol solution of a fraction from the third band of the column.  
The structure of the crystals which was determined by X-ray crystallography showed a 
trinuclear Pt-Co-Pt complex, ([(en)2Co(µ-OH)2(µ-O){Pt(chda)}2]
2+ (3.4), in which the metal 
ions are linked through oxygen bridges (Figure 3-10). Complex 3.4 crystallised in the 
monoclinic space group P21/c. The geometry of Co is octahedral, with two bidentate en 
ligands and two oxido bridges, each to different platinum centres. The geometries of 
platinum can be described as distorted square planar; with two amine groups and two oxido 
bridges, one to Co and another to the other platinum. The cyclohexane rings in the structure 
are disordered, each with different absolute configurations with the ratio of 60/40. One of 
the configurations is shown in pink. The pink stereocentres have the SS configurations and 
the grey stereocentres have the RR configurations (Figure 3-11). The CoPt2O3 has adopted a 






Figure  3-10 The molecular structure of complex 3.4. The three nitrate anions and four water 
molecules omitted are for clarity. The cyclohexane rings exhibited different configurations 
 




There is hydrogen bonding between O2 of the central six-membered ring, O8 of nitrate ion, 
O13 and O14 of the water molecules and the hydrogen atoms on N4, N1, N5 and N7. The 
bond length of H4-O2, H14-O1, H5-O13 and H7-O14 are 2.034(4), 2.175(2), 2.12(3) and 
2.177(17) Å respectively (Figure 3-12). 
 
Figure  3-12 Molecular structure of 3.4 with three nitrate anions and four water molecule omitted for 
clarity in one configuration of disorder. Hydrogen bond lengths [Å]: O2-H4 2.055, O14-H7 2.047, 
O13-H5 2.134, O8-H1 2.175. Selected bond lengths [Å] and angles [°]: Pt1-O2 2.051(7); Pt1-O1 
2.022(8); Pt1-N5 2.039(10); Pt1-N6 2.037(9); Pt2-O2 2.054(9); Pt2-O3 2.031(8); Pt2-N8 2.032(11); 
Pt2-N7 2.042(10); Co1-O1 1.936(8); Co1-O3 1.890(8); Co1-N4 1.953(10); Co1-N2 1.955(10); Co1-N1 
1.947(10); Co1-N3 1.944(10); O1-Pt1-O2 90.2(3); O1-Pt1-N5 91.2(4); O1-Pt1-N6 174.6(4); N5-Pt1-O2 
178.6(4); N6-Pt1-N5 83.8(4); O3-Pt2-O2 89.8(3); O3-Pt2-N8 90.8(4); O3-Pt2-N7 174.7(4); N8-Pt2-O2 
178.0(4); N8-Pt2-N7 84.0(5); N7-Pt2-O2 95.4(4); O1-Co1-N4 91.2(4); O1-Co1-N2 89.3(4); O1-Co1-N1 
175.3(4); O1-Co1-N3 87.9(4); O3-Co1-O1 91.5(4); O3-Co1-N4 92.2(4); O3-Co1-N2 89.2(4); O3-Co1-N1 
89.0(4); O3-Co1-N3 177.4(4); N4-Co1-N2 178.5(5); N1-Co1-N4 93.5(4); N1-Co1-N2 86.0(4); N3-Co1-








Figure  3-13 a) The front and b) the side view of 3.4 of six membered CoPt2O3 unit; showing 
deviations [in Å] of the atoms from the plane (33, -12, 6): Co1 0.412, O1 -0.504, O3 0.004, Pt2 -0.573, 
Pt1 0.132 and O2 0.800 









Although structures of numerous oxido bridged M3 (M: any metal) complexes have been 
studied, very few feature a six-membered metal-oxo ring where different metals are 
present in the ring. 
The crystal structures of [((TPA)Fe)2(μ-MoO4)(μ-O)](OTf)2 (TPA = tris(2-pyridylmethyl)-
amine)[127], Co(bpe)2(V4O12) (bpe = (bis(4-pyridyl)ethylene))
[128] and [Pt3(µ-
OH)3(dpk·H2O)2(dpk)](NO3)3·4.5H2O (dpk = 2,2’-Dipyridylketone)
[129] are shown in Figure 3-
15, 3-16 and 3-17 respectively. The MoFe2O3 unit forms a twisted conformation and the 
CoV2O3 and Pt3O3 units form half chair and chair configurations respectively. The CoV2O3 
system is most similar to our structure. 
 
 
Figure  3-15 a) The molecular structure of [((TPA)Fe2(μ-MoO4)(μ-O)](OTf)2 b) The front view and c) 








Figure  3-16 a) The molecular structure of Co(bpe)2(V4O12) b) The front view and c) the side view of 




Figure  3-17 a) The molecular structure of  [Pt3(µ-OH)3(dpk·̇H2O)2(dpk)]  b) The front view and c) the 
side view of six membered Pt3O3 unit. The six membered unit forms a chair configuration. 
 
 
This crystal structure is clearly different from that proposed for the bulk material of the 
third band based on NMR and mass spectrometry studies. Those studies are consistent with 
the formation of a dinuclear Co-Pt complex, while the X-ray study determined a trinuclear 
Pt-Co-Pt complex with the formula of [(en)2Co(µ-OH)2(µ-O){(Pt(chda)}2](NO3)3·3H2O (3.4). 
The 1H NMR spectrum of crystals (3.4) is shown in Figure 3-18 (bottom). The NMR data are 
consistent with the crystal structure, but importantly is different from that obtained for the 




crystals (Figure 3-18 (bottom)) show 1:2 molar ratios of en ligand vs chda ligand from which 
a ratio of one cobalt vs two platinum is inferred. 
The signals assigned to the en groups in the crystals may be responsible for at least some of 
the impurity signal in the spectra of the bulk sample. Formation of the trinuclear species 
from two equivalents of the dinuclear complex would also produce a mononuclear Co 
species, which could also contribute to the impurity signals. 
 
 
Figure  3-18 Comparison of 1H NMR spectra of the third fraction of the column, 3.2 (top), and the 





The mass spectrum taken from crystals (3.4) contained peaks at m/z = 393.07 and 326.08, 
which are assigned to the [(en)Co(µ-OH)3{Pt(chda)}2-2H
+]2+ and [(chda)Pt(µ-OH)2Pt(chda)]
2+ 




Figure  3-19 Proposed structures of the molecules for which the masses were found by Mass 




Figure  3-20 Experimental (top) and simulated isotope patterns for the highest abundance mass peak 
of the [(en)Co(µ-OH) 3{Pt(chda)}2-2H







Figure  3-21 Experimental (top) and simulated isotope patterns for the highest abundance mass peak 
of the [(chda)Pt(µ-OH) 2Pt(chda)]





The synthetic chemistry used to prepare complex 3.5 is presented in Scheme 3-2. Cisplatin 
[PtCl2(NH3)2] was treated with silver nitrate for 2 days
[125]. The silver chloride precipitate was 
centrifuged and the supernatant was reacted with [(en)2Co(OH)(OH2)]
2+. The reaction 
mixture was stirred for 3 days. The purification of the crude compound by size exclusion 









In the Figure 3-22 the signals at 43.71 and 45.79 ppm are assigned to the desired cis-
dinuclear Co-Pt complex in the 13C NMR spectrum of the crude sample. The small signals 
marked with circles are assigned to a small amount of an equilibrium mixture of cis and 
trans isomers of [(en)2Co(OH)(OH2)]
2+ (see chapter 2). The single signal at 44.48 ppm is 
therefore assigned to a trans-dinuclear Co-Pt complex, since there is only one signal and the 
only alternatives would seem to involve coordination of poor ligands such as nitrate.  
 
Figure  3-22 The 13C NMR spectrum of [(en)2Co(OH)2Pt(NH3)2]
3+ in D2O, 6 h after starting the reaction. 




The 13C NMR spectrum presented in Figure 3-23 was taken 3 days after starting the reaction. 
The value of the cis to trans ratio was changed from 9.49 to 14.12 for the large set of peaks. 
As discussed in chapter 2, the cis complex is always more likely, than the trans, to form 
dinuclear complexes. It presumably takes time for the trans complex to convert to the cis 






Figure  3-23 The 13C NMR spectrum of [(en)2Co(µ-OH)2Pt(NH3)]
3+ ,3 days after starting the reaction 
 
Signals were observed at m/z = 220.54 in the mass spectrum and the isotopic pattern 
simulation with {[(en)2Co(µ-OH)2Pt(NH3)2]
3+-H+}2+ is shown in Figure 3-24. 
 







 3+ (3.6) 
The synthetic chemistry used to prepare complex 3.6 is presented in Scheme 3-3. Cisplatin, 
[PtCl2(NH3)2], was treated with silver nitrate for 2 days
[125]. The silver chloride precipitate 
was centrifuged and the supernatant was reacted with [Co(tren)(OH)(OH2)](ClO4)2. 
 
Scheme  3-3 Synthetic route to obtain [(tren)Co(µ-OH)2Pt(NH3)2]
3+ complex 
 
Although the reaction of [Co(tren)(OH)(OH2)]
2+ and [Pt(chda)(OH2)2] is very similar to those 
discussed above, it was very soon clear that reactions of the Co(tren) system were much 
slower than those of the Co(en)2 system. Ultimately, it was found that the reaction could be 
conducted in two hours, but only if microwave heating was employed. Without microwave 
heating the reaction took weeks. 
The 13C NMR spectrum of [Co(tren)(OH)(OH2)]
2+ is presented in Figure 3-24 a, and contains 4 
signals at 62.10, 60.96, 44.48 and 43.64 ppm. The two former and the two latter signals are 






Figure  3-25 a) The 13C NMR spectrum of [Co(tren)(OH)(OH2)]
2+ in D2O b) The 
13C NMR spectrum of 
the reaction mixture of [Co(tren)(OH)(OH2)]
2+ and [Pt(NH3)2(OH2)2]
2+ in D2O after 2 hours of 
microwave heating 
 
The 13C NMR spectrum of [Co(tren)(OH)(OH2)]
2+ and cisplatin reaction after 2 hours under 
microwave heating is shown in Figure 3-25 b. The signals of [Co(tren)(OH)(OH2)]
2+ have 




59.01, 44.01 and 43.46 ppm are assigned to the dinuclear complex. There are very small 
signals due to unreacted [Co(tren)(OH)(OH2)]
2+ present in the spectrum. Moreover, there 
are a further two new signals at 49.86 and 36.52 ppm. To confirm these two signals belong 
to free tren, a small amount of free tren was added. Subsequently, the integration of signals 
increased. 
To follow the reaction more conveniently, an integration vs time graph is drawn (Graph 3-1). 
The integration of unreacted [Co(tren)(OH)(OH2)]
2+, product and free tren were plotted vs 
time.  The integration of product and unreacted materials are obtained by addition of the 
integration of two signals of carbon atoms next to tertiary amines dividing by the sum of all 
signal integrations. Similarly, the integration of free tren is obtained by addition of two 
signals of free tren dividing by the overall integration. The standard error for signal 




Graph  3-1 Integration of unreacted [Co(tren)(OH)(OH2)]
2+, the product ([(tren)Co(µ-OH)2Pt(NH3)]
3+) 
and free tren vs time in reaction between [Co(tren)(OH)(OH2)]




























Graph 3-1 shows that most of the product formed after 40 minutes heating in a microwave 
and after that, the trend seems linear. The integration of free tren started to increase after 
40 minutes. The formation of dinuclear Co-Pt complex did not go any further after 40 
minutes. This could be due to loss of platinum species in the primary step of reaction. 
The crude compound was purified by size exclusion column chromatography on Sephadex 
G10 resin. 
The first band was taken from the column and evaporated to dryness and gave yellowish oil. 
The 1H NMR data allowed us to identify this material as free tren. The second and third 
bands were collected and evaporated to give reddish oils. The oily residue obtained from 
the second and third bands were characterised using mass spectrometry and NMR 
techniques. The 13C NMR spectrum of the third band is shown in Figure 3-26. 
 
 
Figure  3-26 The 13C NMR spectrum of [(tren)Co(µ-OH)2Pt(NH3)]
3+ after purification by size exclusion 





Mass spectrometry results showed that both the second and the third fractions contain 
[(tren)Co(µ-OH)2Pt(NH3)]
3+; but based the mass spectra (see below), we believe the second 
fraction is the nitrate salt of the complex and the third fraction is the perchlorate salt.  
(Figures 3-27 and 3-28).  
In the mass spectrum of the second fraction, the peaks at m/z = 158.03, 233.54 and 466.09 
are assigned to ([(tren)Co(µ-OH)2Pt(NH3)2]
3+ (Figure 3-27 b), [(tren)Co(µ-OH)2Pt(NH3)2-H
+]2+ 
(Figure 3-27 c) and ([(tren)Co(µ-OH)2Pt(NH3)2-2H
+]+ (Figure 3-27 d)
 ions respectively. The 
simulation of each isotopic pattern is shown below the enlargement of each signal. The 
mass peak and the simulation of the isotopic pattern of the nitrate salt of the complex 
({[(tren)Co(µ-OH)2Pt(NH3)2-H
+](NO3)}
+) is shown in Figure 3-27 e. 
Mass spectrum of the third fraction of [(tren)Co(µ-OH)2Pt(NH3)]
3+ from size exclusion 
column chromatography on Sephadex G10 is shown in Figure 3-28 a. The found peaks at 
m/z = 158.03 and 233.54 are assigned to ([(tren)Co(µ-OH)2Pt(NH3)2]
3+ (Figure 3-28 b) and 
[(tren)Co(µ-OH)2Pt(NH3)2-H
+]2+ (Figure 3-28 c). The isotopic pattern simulations of the found 
peaks are shown below the enlargement of each peak. The mass peak and the simulation of 




+) are shown in Figures 3-27 d 





Figure  3-27 a) Mass spectrum of the second fraction of [(tren) Co(µ-OH)2Pt(NH3)]
3+ on size exclusion 
column chromatography on Sephadex G10. The rest of spectra are the enlargement of the found 
peaks:  experimental (top) and simulated isotope patterns (bottom) for the highest abundance mass 
peak of b) [(tren)Co(µ-OH)2Pt(NH3)2]
3+ ion c) [(tren)Co(µ-OH)2Pt(NH3)2-H
+]2+ ion,  d) [(tren)Co(µ-
OH)2Pt(NH3)2-2H
+]+ ion and e) {[(tren)Co(µ-OH)2Pt(NH3)2-H
+](NO3)}






Figure  3-28 a) Mass spectrum of the third fraction of [(tren) Co(µ-OH)2Pt(NH3)]
3+ on size exclusion 
column chromatography on Sephadex G10. The rest of spectra are the enlargement of the found 
peaks: experimental (top) and simulated isotope patterns (bottom) for the highest abundance mass 
peak of b) [(tren)Co(µ-OH)2Pt(NH3)2]
3+ ion, c) [(tren)Co(µ-OH)2Pt(NH3)2-H
+]2+ ion d) {[(tren)Co(µ-
OH)2Pt(NH3)2](ClO4)2}
+ ion  and  e) {[(tren)Co(µ-OH)2Pt(NH3)2-H
+]( ClO4)}






The synthetic route for preparing the title complex is presented in Scheme 3-4. [PtI2(chda)] 
was treated with silver nitrate for 2 days[125]. The silver iodide precipitate was centrifuged 
and the supernatant was reacted with [Co(tren)(OH)(OH2)](ClO4)2. The reaction mixture was 
heated in over the 2 hour period of 90 sec bursts in a microwave. 
 
Scheme  3-4 Synthetic route to obtain [(tren)Co(µ-OH)2Pt(chda)]
3+, complex 3.7. 
 
The product was purified using cation exchange chromatography on CM Sephadex. The 
column was eluted with NaNO3 solutions. The first band was collected, evaporated and gave 
a pink powder. The product collected from the second and third bands gave a reddish slurry 
after evaporation of the solvent. The compounds obtained from second and third bands 
were characterised using mass spectrometry and NMR techniques. Crystals from the first 
band were obtained by slow evaporation of a water-methanol solution of the fraction. They 
were also characterised by NMR and X-ray crystallography. 
X-ray crystallography determined the first fraction to be [Co(tren)(OH2)(ONO2)](NO3)2 (3.8), 





Figure  3-29 The molecular structure of 3.8, with two nitrate anions omitted for clarity. Hydrogen 
atoms are omitted for clarity, except those on the water ligand 
 
 
Figure  3-30 The asymmetric  unit of complex 3.8 with two nitrate anions and hydrogen atoms 
omitted for clarity. The chelate ring of the tren is disordered over two different conformations, and 





The molecular structure of 3.8 is shown in Figure 3-29. The molecule is disordered in the 
asymmetric unit which generates disorder by symmetry in the whole molecule. The 
asymmetric unit of the molecule is shown in Figure 3-30. 
The NMR data for complex 3.8 are consistent with the crystal structure. The four signals at 
62.21, 60.62, 43.93 and 43.60 ppm are assigned to four kinds of carbon atoms of the tren 
ligand. The peaks at m/z 266.06, 203.07 and 102.03 in the mass spectrum, corresponding to 
[Co(tren)(ONO2)-H
+]+, [Co(tren)-2H+]+ and [Co(tren)(ONO2)-2H
+]2+,  were also observed. 
The product, [(tren)Co(µ-OH)2Pt(chda)]
3+ (3.7), came in the third band from the column with 
0.3 M eluent. The fraction was desalted firstly by methanol and acetone extraction and 
secondly by size exclusion column chromatography on Sephadex G10. The complex was 
characterised by NMR and mass spectrometry techniques. The isotope pattern at m/z 
273.08 can be assigned to [(tren)Co(µ-OH)2Pt(chda)-H
+)]2+ (Figure 3-31) 
 
Figure  3-31 Experimental (top) and simulated isotope patterns (bottom) for the highest abundance 






The 1H and 13C NMR Spectra of 3.7 are assigned using COSY and HSQC techniques (Figures 3-




Figure  3-32 The 1H NMR spectrum of 3.7 on D2O. The signals marked by red colour are assigned to 
Ha,a’,f,f’. The signals marked by pink colour are assigned to Hb,b’,e,e’. The signal marked by blue 
colour is assigned to Hc,c’ and the signal marked by green colour is assigned to Hd,d’.  The 







Figure  3-33 The 1H-1H COSY spectrum of 3.7 in D2O. The squares drawn by blue colour show the 
correlations between tren protons on cobalt and those marked by red colour show the correlation of 
protons of chda ligand on platinum. The signals marked by green circles are impurities. 
 
In the 13C NMR spectrum, the four peaks at 62.22, 61.89, 44.5 and 44.27 ppm are assigned 
to four kinds of carbon atoms of tren ligand on Co (Figure 3-34). The three peaks at 62.22, 
31.69 and 24.02 ppm are assigned to the three kinds of carbon atom present in the 











Figure  3-34 The 13C NMR spectrum of 3.7 in D2O. The cyclohexane carbon atoms are assigned by 






Figure  3-35 The 1H-13C HSQC spectrum of 3.7 in D2O. The blue and red lines show the correlation 
between hydrogen and carbon atoms of tren ligand on Co and chda ligand on platinum respectively. 
The signals marked by green circles are impurities 
 
3.3 Overview on cobalt-platinum chemistry 
The isolation and purification of [Co(µ-OH)2Pt] complexes from the reactions was quite 
challenging. Different methods such as recrystallisation and solvent extraction have been 
used in attempts to isolate the compounds but they did not work. Eventually, the use of ion 
exchange column chromatography came closest to achieving purification although this still 
did not give pure complexes. Purification of [(en)2Co(µ-OH)2Pt(chda)]
3+ and [(tren)Co(µ-
OH)2Pt(chda)]
3+ complexes were attempted on CM and SP Sephadex columns, and CM 
Sephadex gave better isolation. An SP column did not separate the bands completely and 
each fraction contained a huge number of impurities. 
Purification of complexes by CM sephadex was associated with some problems. First of all 
the fractions did not elute as separate bands except the first band; but generally the 




the isolation had to be done as quickly as possible (which is difficult because water flow 
through the column is always slow), otherwise, the Co precursor would react with 
carboxylate groups of the column. Lastly, the majority of the last fraction stuck to the 
column presumably due to complexation with the carboxylate groups of the Sephadex. 
Purification of [(en)2Co(µ-OH)2Pt(NH3)2]
3+ and [(tren)Co(µ-OH)2Pt(NH3)2]
3+ complexes were 
attempted on size exclusion column chromatography on Sephadex G10. This column worked 
better for [(tren)Co(µ-OH)2Pt(NH3)2]
3+ and gave 3 bands. 
Despite the fact that ion exchange chromatography can be used to obtain samples of 
dinuclear complexes that are relatively pure, there is also clear evidence that these 
complexes decompose while on the column and, on occasion, during evaporation of the 
eluates. The crystal structure of 3.4 might be good evidence describing the chemistry 
happening at least in the purification process of [(en)2Co(µ-OH)2Pt(chda)]
2+ which may be 
very similar for other dinuclear [Co(OH)2Pt] complexes. Having [Co(µ-OH)2Pt], a second 
platinum could coordinate to this platinum and the substitution chemistry results in the 
trinuclear compound which is shown in crystal structure (3.4) and eventually either 
platinum or cobalt (in a reaction with the carboxylate group of the column) leaves. If Co 
leaves, closing of the bridging ligand gives a diplatinum complex which its mass peak was 
found in mass spectrum. If platinum leaves, we may end up with a Co(µ-OH)Pt complex. 
Some evidence in support of this proposal is the occasional precipitation of yellowish 
powder from early fractions eluted from the column. The powder was later confirmed to be 
Pt(chda) by NMR with an unknown counter-ion. The 1H NMR spectrum of the yellow powder 






Figure  3-36 The 1H NMR spectrum of yellow precipitation from third fraction in d6 DMSO 
 
The intense red colour that remained on the columns necessarily means that the yield of the 
reactions cannot be high. 
 
3.4 Conclusion  
The key conclusion of this study is that dinuclear Co(µ-OH)2Pt complexes can be made, but 
we have been unable to isolate them in pure form. The synthesis of dinuclear Co(µ-OH)Pt 
complexes has been proven by perfectly matched isotopic patterns in mass spectrometry 
and NMR studies. The crystals gained from this experiment (3.4) are trinuclear, suggested 
the lability of the Co(µ-OH)Pt complexes.  
Attempts at purufying these complexes by using cation exchange chromatography on CM 
Sephadex and size exclusion column chromatography on Sephadex G10 were not succesful. 
None of these methods give the pure compounds in good yields.  
The yield of the reactions are not high due to the side products produced and also based on 





























The goal of our study is to prepare a series of Co(µ-OH)2Pt complexes which may have 
potential to be anticancer drugs. Our initial efforts to synthesise dinuclear complexes 
containing Co(III)-amine systems resulted in mixtures of several other complexes with the 
dinuclear complexes we sought. Separations and isolation of the dinuclear complexes from 
these systems proved to be very challenging and were ultimately only partially successful.  
Many of the Platinum(II) complexes whose isolation has been reported in the literature have 
no overall charge. Therefore, we attempted to synthesise neutral dinuclear complexes. 
Nitrilotriacetate (nta), as a L3- ligand, was chosen for coordination to the Co(III) centre, and 
with two hydroxido bridging ligands between the Co(III) and platinum(II) ions, the overall 
charge of the resulting complex will come to zero, providing the remaining ligands on the 
platinum(II) centre are neutral.  
Nitrilotriacetate normally acts as a tetradentate ligand, binding through the nitrogen atom 
and three carboxylate oxygen atoms to a metal ion[130]. The first attempt to synthesise a 
Co(III) complex of nta was reported by Mori et al.[131], but the chemistry is complicated by a 
dimerisation reaction[132]. Mori prepared a blue-coloured Co-nta complex by addition of 
CoCl2·6H2O and nta in potassium bicarbonate solution (2.5 M) and oxidising it by addition of 
hydrogen peroxide. This blue complex was formulated as α-K2[Co(nta)(H2O)(OH)]·2H2O 
(Figure 4-1). The filtrate of the reaction mixture was then acidified and reddish violet 




K2[Co(nta)(H2O)(OH)]·2H2O (Figure 4-1). The α and β complexes were postulated to differ 
only in the location of the aqua proton (see Figure 4-1). The aqua-hydroxido isomerism is 
possible in the solid state but is unlikely in solution since rapid proton exchange would be 
expected to render the suggested α and β forms indistinguishable, particularly in aqueous 
solution. 
 
Figure  4-1 Structures of α- [Co(nta)(H2O)(OH)]⁻ and β-[Co(nta)(H2O)(OH)]⁻ proposed by Mori
[131] 
 
These formulations were based on elemental analyses and the bonding of an aqua and a 
hydroxide ligand was predicted for the remaining two bonding sites around the cobalt ion 
based on matching the analysis. Another study however proved the formulation was 
wrong[132]. A crystal structure determination of the so-called blue α-
K[Co(nta)(H2O)(OH)]·2H2O with the only difference being the presence of Cs
+ cations, 





Figure  4-2 The crystal structure of anion of Cs2[Co2(nta)2(µ-OH)2]·4H2O
[132] 
 
A UV-Vis spectral study of the different Co-nta complexes present at different pH values led 
to the conclusion that the following reactions were occurring[132]: 
 
The hydroxide bridges can be broken in a reversible protonation step to form the diaqua 
complex, [Co(nta)(H2O)2]. The diaqua complex forms the aqua-hydroxo complex, 
[Co(nta)(H2O)(OH)]
-, with the addition of base in a reversible step.  
 
4.2 Results and Discussion  
4.2.1 Failure of the literature method to produce [Co(nta)(H2O)2] 
[Co(nta)(OH2)2] was synthesised using a different method to that described in the  




Our very first effort to synthesise [Co(nta)(OH2)2] (4.1) complex was based on the Mori 
procedure, and gave a dinuclear complex of the formula of K2[Co2(nta)2(µ-OH)2]·6H2O (4.2) 
in the first step; and [Co(nta)(OH2)2] should have been obtained by acidifying the filtrate of 
the dinuclear complex. Although, we did not end up with the desired complex (4.1) by 
following this method, we did obtain some blue square crystals by slow evaporation of 
solvent, and these proved to be K2[Co2(nta)2(µ-OH)2]·6H2O (4.2).   
X-ray crystallography determined the structure of the K2[Co2(nta)2(µ-OH)2]·6H2O to be that 
shown in Figure 4-3. This compound crystallised with half formula units in the asymmetric 
unit. Co1 is octahedrally coordinated to one N atom, three O atoms of the nta ligand and 
two bridging O atoms.  
 
Figure  4-3 The crystal structure of the anion of 4.2. Water molecules and hydrogen atoms are also 
omitted for clarity 
 
As mentioned above, the crystal structure of Cs2[Co2(nta)2(µ-OH)2] has already been 




group to that of the cesium salt. The crystal data for our crystal and those of the published 
structure are compared in Table 4-1. 
 
Cs2[Co2(nta)2(µ-OH)2]·4H2O K2[Co2(nta)2(µ-OH)2]·6H2O 
a = 19.640(2)  
b = 19.640(2)  
c = 12.581(2) 
a = 12.6044(13) 
b = 9.2309(7) 
c = 13.0780(11) 
Tetragonal, I41/a 
α = 90 
β = 90 
γ = 90 
Monoclinic, P21/c 
α = 90 
β = 110.233(11)°  
γ = 90 
 
Table  4-1 Crystal data comparison of Cs2[Co2(nta)2(µ-OH)2]·4H2O and K2[Co2(nta)2(µ-OH)2]·6H2O 
 
The dinuclear anion of 4.2 and the published structure both crystallised with half formula 
units in the asymmetric unit. The cobalt centres are octahedrally coordinated to the 
tetradentate nta ligand and two hydroxido bridging ligands. 
 
4.3 Results from unsuccessful attempts to synthesise [Co(nta)(H2O)2] 
 
Our attempts to synthesise [Co(nta)(OH)2] by different methods resulted in the isolation of 
other complexes, as shown in Schemes 4-1, 4-2, and 4-3. Crystals of 4.3, 4.4 and 4.5 were 
obtained. The structures of these compounds are also shown in the schemes. 
Cobalt is octahedrally attached to a tetradentate nta ligand and two carboxylate oxygen 
atoms of two other nta ligands in crystals of 4.3. 
In the crystal structure of 4.4, Co1 is octahedrally attached to a tetradentate nta ligand and 




The crystal structure of 4.4 shows that cobalt is octahedrally coordinated to a nta ligand 















Crystals of 4.3 have been reported, with two different preparation methods, in the 
literature[133],[134]. In one method, a mixture of Co(NO3)2, NaHPO4 and nta was stirred at 
room temperature and then the reaction mixture was transferred to a sealed Teflon-lined 
stainless steel autoclave at 160 °C. The crystals of 4.3 formed after 4 days[133]. In the other 
method, a mixture of nta, Co(CH3COO)2·4H2O and water was stirred, and then NaOH 
solution was added to adjust the pH to 5–6. Three weeks later, purple crystals of 4.3 were 
obtained[134]. 
In a new synthetic method, the disodium salt of Hnta and KHCO3 were stirred at 80 °C in 
water and then CoCl2·6H2O and H2O2 were added. The formed powder was filtered and the 
powder suspended in water refluxed for two hours and then was filtered. The Powder 2 
formed in the filtrate on cooling. Crystals of 4.3 were obtained by hydrothermal 
recrystallisation of Powder 2 at 60 °C.  
Crystals of 4.4 have also been reported in literature, and were obtained by the following 
procedure[135]. The nta ligand was dissolved in water at 80 °C and the pH was adjusted to 6 
by addition of NaOH solution. Co(CH3COO)2·4H2O was then added to the reaction mixture. 
The reaction was filtered and crystals were obtained upon standing the filtrate for two 
months.  
We obtained crystals of 4.4 by dissolving Powder 2 in water and allowing it to evaporate 
slowly.  
In order to check that the single crystals that were analysed are representative of the bulk, 
the X-ray powder diffraction (PXRD) patterns were recorded.  As shown in Figure 4-4, the 




calculated from the solution to the single crystal studies[133],[134]. The peak positions found 






Figure  4-4 Experimental and Calculated PXRD patterns for crystal 4.3, 4.4 and Powder 2 
 
Thus, the methods shown in Scheme 4-1 produce crystalline polymeric Co-nta complexes 
that have been previously synthesised by different but related methods. 
Crystals of 4.5 were prepared by the method shown in Scheme 4-2. The disodium salt of nta 
was suspended in water and the pH was adjusted to 7.3 by addition of a solution of NaOH. 


















heated at 70 °C in water and then filtered. Powder 4 formed in the filtrate and was collected 
and transferred to a hydrothermal bomb at 50 °C in water. The crystals formed, in this hot 
solution after a week. 
A single crystal X-ray analysis revealed that these crystals of 4.5 were the same as those 
reported in the literature, which were obtained through slow evaporation of an equimolar 
mixture of CoSO4·7H2O and nta·K2 in water (both commercial grade)
[136]. 
 





In order to check that the single crystals that were analysed are representative of the bulk, 
the X-ray powder diffraction (PXRD) patterns were recorded.  As shown in Figure 4-5, the 
peak positions in the experimentally determined pattern are mostly in agreement with that 
calculated from the solution to the single crystal study. 
The PXRD pattern of Powder 4 is mostly in agreement with the crystalline material but extra 
peaks are also observed, indicating that something else is also present in the powder. 
 
 
Figure  4-5 Experimental and simulated PXRD patterns for crystal 4.5 and powder 4 
 
A different crystalline material was obtained using the procedure shown on Scheme 4-3. 
The ligand was suspended in water and NaOH was added until the pH was approximately 7. 
Co(NO3)2 was added to reaction mixture. The pH of the reaction dropped to 4.2.  The 
reaction was stirred at room temperature and after a while a pink precipitate formed. The 






















reaction was heated to 90 °C. The solution was left for some days and product formed as 
pink crystals (4.6). 
 
Scheme  4-3 Synthetic route to obtain crystals of 4.6 
 
The structure of the crystals (C12H29.8Co2.5N2O21.4)∞ (4.6) was determined by X-ray diffraction 
to be that of a polymer (Figure 4-6). The repeating unit has the formula [C12H21N2O17Co2.5]. 
The crystal 4.6 contains three kinds of cobalt centres. Co1 is octahedrally coordinated to 
two nta ligands through two arms of each. It means Co1 is coordinated to four carboxylate 
oxygen atoms and two nitrogen atoms of two nta ligand. The non-coordinated arm of the 
nta ligand to Co1, chelates to two Co2 centres through O9 and O10. Another non-
coordinated arm of the nta ligand to Co1, coordinated to Co3 monodentately through O15. 
Co2 unit is a dinuclear complex formed through O13. Co2 is coordinated to bridging oxygen 
atoms (O13), two water molecules (O11 and O12) and two carboxylate oxygen atoms of the 
nta ligand. Co3 is coordinated to four water molecules and two carboxylate oxygen atoms of 
the nta ligand. Selected bond lengths and bond angles of 4.6 are given in Tables 4-2 and 4-3. 
The polymer is generated by CO2 being in a centrosymmetric dimer and the coordination 
sphere around C3 being generated by a centre of symmetry. The packing diagram of 4.6 is 












Bond length [Å] 
Co1-O1 1.889(2) Co2-O13 2.062(2) 
Co1-O5 1.883(2) Co2-O12 2.062(2) 
Co1-O3 1.889(2) Co2-O11 2.037(3) 
Co1-O7 1.892(2) Co3-O15 2.115(2) 
Co1-N2 1.975(3) Co3-O16 2.087(2) 
Co1-N1 1.986(3) Co3-O17 2.090(3) 
Co2-O10 2.067(2) Co2-O9 2.070(2) 
 


















Bond angle [°] 
O1-Co1-O3 89.21(12) C10-O10-Co2 124.5(2) 
O1-Co1-O7 91.90(12) C12-O15-Co3 125.4(2) 
O1-Co1-N2 90.99(11) C1-O1-Co1 115.2(2) 
O1-Co1-N1 87.28(11) C5-O5-Co1 115.2(2) 
O5-Co1-O1 177.78(11) C3-O3-Co1 115.4(2) 
O5-Co1-O3 88.87(11) C7-O7-Co1 114.2(2) 
O5-Co1-O7 90.01(11) C8-N2-Co1 103.2(2) 
O5-Co1-N2 88.02(10) C8-N2-C11 110.6(3) 
O5-Co1-N1 93.75(10) C8-N2-C6 111.3(3) 
O3-Co1-O7 178.73(12) C11-N2-Co1 112.00(19) 
O3-Co1-N2 93.66(10) C6-N2-Co1 106.44(19) 
O3-Co1-N1 87.37(10) C6-N2-C11 112.8(3) 
O7-Co1-N2 85.70(10) C9-N1-Co1 114.41(19) 
O7-Co1-N1 93.30(10) C9-N1-C2 110.1(3) 
N2-Co1-N1 177.97(11) C9-N1-C4 110.6(3) 
O10-Co2-O13 83.45(9) C2-N1-Co1 104.1(2) 
O11-Co2-O10 89.23(10) C4-N1-Co1 105.1(2) 
O11-Co2-O13 171.39(9) C4-N1-C2 112.3(3) 
O11-Co2-O12 88.70(11) O16-Co3-O15 89.47(9) 
O12-Co2-O10 101.01(9) O16-Co3-O17 90.49(10) 
O12-Co2-O13 88.25(10) O17-Co3-O15 92.98(10) 
 
Table  4-3 Selected bond angles for 4.6 
 
The X-ray diffraction study showed complex 4.6 formed a mixed valence polymeric 
structure, based on the bond lengths.  The Co3–O and Co2-O distances are in the range 
2.062–2.205 A˚, comparable to the corresponding values found in Co(II) complexes[137],[136],. 
The Co(1)–O distances 1.889 A˚ and the Co(1)–N distance is 1.986 and 1.975 A˚, comparable 
to the corresponding values found in other Co(III) complexes. The packing structure of 4.6 is 
shown in Figure 4-7. 
The 1H NMR spectrum of 4.6 is shown in Figure 4-8. There are three sets of peaks, but they 

















4.3.1 Synthesis and characterisation of [Co(nta)(OH2)2] 
 
We synthesised [Co(nta)(OH2)2] in a straight-forward manner by addition of a lesser amount 
of potassium bicarbonate in comparison with Mori’s method, giving an acidic medium 
(pH~3) for the reaction between CoCl2 and the disodium salt of the nta ligand with hydrogen 
peroxide as the oxidant. Although we ultimately synthesised pure [Co(nta)(OH2)2] complex, 
the yield of the reaction (22%) is lower than the literature (40%). 
The geminal hydrogen atoms are indicated in red and blue in Figure 4-9. The 1H NMR 
spectrum of [Co(nta)(H2O)2] contains an AB multiplet and a singlet peak (Figure 4-10). These 
hydrogen atoms are inequivalent and couple to each other, leading to the AB system. The 
hydrogen atoms indicated in black are equivalent and they appear as a singlet in the 1H 
NMR spectrum. 
The 13C NMR spectrum of [Co(nta)(OH2)2], contains four signals (Figure 4-11). The peaks at 
178 and 168 ppm are assigned to the two equivalent axial carboxylic carbon atoms, and one 
equatorial carboxylic carbon atom, respectively, based on the fact that the signal at 178 
ppm has twice the intensity of that at 168 ppm. Two other signals at 66.92 and 62.69 ppm 
are assigned to the two equivalent axial methylene carbon atoms and one equatorial 





Figure  4-9 Structure of [Co(nta)(H2O)2] (4.1) 
 










4.4 Preparation and Characterisation of Neutral [Co(µ-OH)2Pt] Complexes 
 
A general overview of the synthesis of complexes of the general form [(nta)Co(µ-OH)2Pt(L)] 
(L = chda, en, (NH3)2) is presented below, in Scheme 4-4. [Pt(L)Cl2] was treated with silver 
nitrate to displace halide ligands[125]. The silver halide precipitate was centrifuged and the 
pH of the supernatant was adjusted to 5 to match that of the solution of [Co(nta)(OH2)2] in 
water. The supernatant was added to a solution of [Co(nta)(OH2)2] (pH=5). The reaction 
mixture was stirred. The products (4.7, 4.12 and 4.16) precipitated from the reaction 






Scheme  4-4 General synthetic route to produce complexes of the general formula of 
[(nta)Co(µ-OH)2Pt(L)] (L = chda, en, (NH3)2) 
 
 
The elemental analysis results are consistent with the formula of [Co(nta)(µ-OH)2Pt(L)]·2H2O 
for the complexes. The characterisation of these complexes is limited due to their very low 
solubility in most solvents. 
The IR spectra of the synthesised complexes are shown in Figure 4-13. The IR spectra of the 
three dinuclear complexes look very similar, as expected. There are significant differences 




bound to the platinum centre. The carbonyl stretching frequency of 4.7, 4.12 and 4.16 are 
observed at 1621, 1614 and 1621 cm-1 respectively. 
 
Figure  4-12 The IR spectra of a) [(nta)Co(µ-OH)2Pt(NH3)2] (4.16), b) [(nta)Co(µ-OH)2Pt(en)] (4.12) and 




4.4.1 NMR studies 
4.4.1.1 NMR studies of [(nta)Co(µ-OH)2Pt(chda)] in DMSO, 4.7 
[Co(nta)(µ-OH)2Pt(chda)] (4.7), shown in Figure 4-13, is insoluble in most of the common 
solvents except for some solubility in DMSO. The 1H NMR spectrum of [Co(nta)(µ-
OH)2Pt(chda)] in d




Figure  4-13 Arrangement of the hydrogen atoms on amine groups 
 
The key point about 4.7 is the asymmetry of the molecule due to the amine chirality. One 
amine is trans to equatorial oxygen atom of nta and another amine is trans to the nitrogen 
atom of the nta. It means all hydrogen and carbon atoms on chda are inequivalent. 
Moreover, the axial arms of the nta ligand are not equivalent anymore. We expect to see 10 
sets of signals for the cyclohexane hydrogen atoms, 4 signals for four different hydrogen 
atoms on the amine, two sets of AB systems for the methylene hydrogen atoms on the axial 







Figure  4-14 The 1H NMR spectrum of 4.7 in d6 DMSO at 25 °C 
 
The 1H NMR spectrum of 4.7 in d6 DMSO at 25 °C showed 6 sets of signals from 1 to 2.5 ppm 
(Figure 4-14). This is the region that signals assigned to the chda ligand are observed, based 
on studies described in earlier chapters. The appearance of this part of the spectrum is also 
similar to other chda spectra discussed in earlier chapters. We have 10 different hydrogen 
atoms on carbon atoms in the chda ligand on platinum. Eight of the hydrogen atoms may 
coincidentally overlap each other and appeared as four sets of signals and two other 
hydrogen atoms appeared as two sets of signals with smaller integrations in the 1H NMR 
spectrum (Figure 4-14). The signals from 3.5 to 4.7 ppm belong to nta ligand, however it is 
not clear which signals belong to which protons within the ligand. This is largely due to of 
peak broadening and overlapping peaks. The rest of the signals from 5 to 6.5 are assigned to 
amine hydrogen atoms. The number of signals for the nta region shows there are more than 
one Co(nta) complex present in the solution. We speculate that this mixture of complexes is 




In order to explore the reactivity of the complex with DMSO, another 1H NMR spectrum was 
taken at high temperature (80 °C, Figure 4-15 b). The 1H NMR spectrum (80 °C) showed five 
sets of signals in the chda region. The region assigned to the nta ligand contains three AB 
multiplets and two singlets.  
There are also four broad signals from 5.6 to 6.4 ppm assigned to four amine hydrogen 
atoms. The signals assigned to the amine protons at 5.2 ppm disappeared (Figure 4-15 b). 
This may mean at least one of the OH bridging ligands is replaced by DMSO. The 1H NMR 
spectra presented in the literature indicate that [Pt(en)Cl2] has a resonance at 5.31 ppm 
which is assigned to the equivalent amine protons. For [PtCl(en)(dmso)]+, amine protons 
have sets of resonances at 6.31 and 6.06 ppm due to inequivalent amine protons[138]. Based 
on this result[138], we may infer the spectrum shown in Figure 4-15 a is a mixture of the 
dinuclear complex and the complex reacted to DMSO. The peak at 5.25 ppm may also be 
assigned to the amine protons of the dinuclear complex (4.7) and the peaks between 6 and 
6.5 ppm may pertain to amine protons after having DMSO as a ligand attached to platinum. 
In other words, we think the dissolution of the complex is tied to the reaction with the 
solvent. 
The NMR tube containing the sample was left for some hours at room temperature, and 
then a 1H NMR spectrum was taken again (Figure 4-15c). This spectrum is very similar with 





Figure ‎4-15 The 1H NMR spectrum of [Co(nta)(µ-OH)2Pt(chda)](4.7) a) at 25 °C; b) at 80 °C; c) 




The 1H-1H COSY spectrum showed a cross peak between H1 and H2 of the chda ligand and 
the amine protons. The chemical shifts of the amine protons show they are trans to DMSO. 
The broad signal at 5.25 ppm possibly belongs to the amine hydrogen atoms of the 
dinuclear complex (4.7). As this signal disappeared in the spectrum at high temperature, it 
may suggest that most of 4.7 reacted with DMSO.  
The 13C NMR spectrum was taken once in 80 °C and again at 25 °C after cooling down the 
sample (Figure 4-16) 
We observed 6 signals for the cyclohexane ring, as we expected for 4.7, since all of the 
carbon atoms of the cyclohexane ring become inequivalent after binding of platinum to 
Co(nta) (Figure 4-16a). The existence of at least four signals in the carboxylate carbon region 
and four signals in the methylene region would mean having more than one complex.  The 
1H NMR spectrum already supported cleavage of one of the hydroxido bridging ligands by 
DMSO. The number of signals may suggests two compounds are present. We speculate 4.8 
and 4.9 are present at the same time. If we have complexes 4.8 and 4.9, we still expect to 
see 6 signals for chda, since the chda ligand may not be affected by the difference between 
having water or DMSO attached to cobalt; but more than one set of signals should be seen 
for nta ligand on cobalt. 
The 13C NMR spectrum taken at 25 °C, after cooling down is not very different from the one 






Figure  4-16 13C NMR spectrum of [Co(nta)(µ-OH)2Pt(chda)] a) at 80 °C and b) after cooling down to 
25 °C. The enlargement of each spectrum is shown underneath of each spectrum 
 
Using the suggested mechanism shown in Scheme 4-5 helps to explain the NMR spectra. 
The spectrum in Figure 4-16a may represent having a mixture of 4.7, 4.8 and 4.9.  
Square planar platinum complexes (16e-, d8) usually undergo associative ligand 
substitution[139]. In the associative mechanism, the M-Nu bond is formed before the M-X 




to platinum is usually through sulfur[140].The substitution of DMSO onto platinum should 
therefore be through sulfur, since platinum is a soft Lewis acid. Dissociative ligand 
substitution is most favored in coordinatively saturated 18e- complexes (e.g. d6 octahedral 
Co(III) complexes)[141]. In the dissociative mechanism, the M-X bond is fully broken before 
the M-Nu bond forms, thereby avoiding an energetically unfavorable 20e- intermediate. As 
Co(III) is a hard Lewis acid, coordination of DMSO is expected to be from oxygen, and this is 
seen in the literature [142],[143]. 
 
 








4.4.1.2 NMR studies of [(nta)Co(µ-OH)2Pt(en)], 4.12 
 
 
The complex (4.12) is insoluble in d6 DMSO at 25 °C, and we could not record the 1H NMR 
spectrum at room temperature. Therefore, the NMR spectrum was taken in 80 °C (Figure 4-
17a).  
 
Figure  4-17 a) The 1H NMR spectrum of [Co(nta)(µ-OH)2Pt(en)] in d
6 DMSO at 80 °C b) The 1H NMR 
spectrum of [Co(nta)(µ-OH)2Pt(en)], 3 h after cooling down to 25 °C 
We expected to see one set of AB mutiplets and a singlet for the nta ligand on the cobalt 




group on the platinum component. But the observation from the 1H NMR at 80 °C showed 
two sets of AB multiplets and two singlet peaks for the nta ligand (Figure 4-17a). There are 
also two peaks at 6.25 and 6.19 ppm and one peak at 2.00 ppm which are assigned to 
hydrogen atoms on the amine groups and a methylene group of the en ligand that is 
attached to platinum, respectively. The COSY spectrum showed there is another peak 
underneath the DMSO peak which is also assigned to the en ligand on platinum (Figure 4-
18). 
 
Figure  4-18 The 1H-1H COSY spectrum of [(nta)Co(µ-OH)2Pt(en)](4.12) in d
6 DMSO at 80 °C 
 
The two peaks at 2.5 and 2.59 ppm assigned to en ligand have a cross peak with the amine 
protons at 6.00 and 6.08 ppm respectively. This means the en protons on platinum are trans 
to different ligands. The cross peaks between 3.5 and 4.3 ppm are related to the nta ligand 
on cobalt. Insolubility of 4.12 in DMSO at room temperature and its partial solubility at 80 °C 




produce different, more soluble complexes. It may mean DMSO becomes a ligand on the Pt 
component and the NMR results are consistent with having a mixture of the 4.13 and 4.14. 
The NMR tube containing the sample was left for some hours at room temperature, and 
then the 1H NMR spectrum was taken again (Figure 4-17b). The 1H NMR spectrum contains 
two sets of signal for the nta ligand and one set of signals for the en ligand. 1H NMR spectra 
described in the literature indicate that [Pt(en)Cl2] has a resonance at 5.31 ppm for 
equivalent amine protons, and [Pt(en)(dmso)Cl]+, has a set of resonances at 6.31 and 6.06 
ppm due to inequivalent amine protons. The chemical shift the amine hydrogens appeared 
at is also consistent with coordination of DMSO to platinum[138]. The results may suggest the 
substitution of two DMSO ligands on to platinum (4.15) as there is only one signal for 
hydrogen atoms of the amine groups. On the other hand, two sets of signals for nta may 
represent having the mixture of 4.1 and 4.11 at the same time. Dissolution of the NMR 
sample in DMSO after cooling down to room temperature demonstrates that the complex 
actually reacted with DMSO.  
The 13C NMR spectrum of 4.12 in d6 DMSO at high temperature measured in a short 
experiment time was very noisy and we were unable to get any information out of it. 
Therefore, another 13C NMR was taken 6 hours after cooling down the sample tube for a 
longer time (Figure 4-19).  
There are three peaks for axial carboxylate carbon atoms at about 180 ppm and two peaks 
for equatorial. As the number of carbon signals for equatorial and axial carbon atoms should 
be equal and one of the carbon signals is taller (in 172.08 ppm), there may be a another 
signal underneath the signals at about 172 ppm.  There are also three signals for the axial 




carbon atoms. There should be one signal underneath because of the same reason brought 
for equatorial carboxylate carbon atoms. The 13C NMR is a very good indicator that 4.12 has 
reacted with DMSO. 
 
Figure  4-19 The 13C NMR spectrum of [Co(nta)(µ-OH)2Pt(en)] in d





The number of signals for en ligand and nta are consistent with having both complexes 4.13 
and 4.14 present in solution (Scheme 4-6). In this way, we expect to see two sets of signals 
for the nta ligand on cobalt and two signals for en. 
The suggested mechanism for the substitution of DMSO by hydroxido bridging ligand is 
demonstrated in Scheme 4-6. This mechanism is analogous to that of suggested for the 













4.4.1.3  [(nta)Co (µ-OH)2Pt(NH3)2], 4.16 
 
The title complex has a mirror plane containing the axial arm of the nta attached to the 
cobalt, the bridging hyroxido ligands and platinum with the amine ligands. The amine 
ligands on platinum are different because one is trans to the equatorial O and another is 
trans to the equatorial N atom of the nta ligand. But they might not be affected by this 
difference in NMR since they are too far from nta ligand.  We expect to see one set of AB 
system multiplets and a singlet for the nta ligand on cobalt and a signal for amine protons 
on platinum in the 1H NMR spectrum of [(nta)Co(µ-OH)2Pt(NH3)2] (4.16). 
Compound 4.16 was slightly soluble in DMSO. The 1H NMR spectrum taken at 25 °C is shown 
in Figure 4-20a. This NMR spectrum is noisy, but more than one set of signals for the nta 
ligand on cobalt is observable. In order to explore the extra signals and the peak broadening 
that occur due to a reaction with DMSO, another NMR spectrum was taken at 80 °C (Figure 
4-20b). There are two sets of signals for the nta ligand on cobalt and two sets of signals for 
amine ligands on platinum which indicate that more than one compound is there. The 
number of signals suggests we either have a mixture of 4.16 and 4.19 or 4.17 and 4.18 
(Scheme 4-7). However, having 4.16 seems less likely, since most of the compound, unlike 
the starting materal remains soluble in DMSO after cooling down. It means that the 
apparent solubility of 4.16 is due to reaction with DMSO. Evidence from 1H NMR studies of 
cisplatin is consistent with DMSO reacting with 4.16. The chemical shift for amine protons of 
cisplatin is 3.92 ppm. The NMR tube containing cisplatin in DMSO was left for half an hour 
and another 1H NMR spectrum was taken (Figure 4-21). A new signal appearing at 4.69 ppm 
represents that DMSO reacted with platinum. Chemical shifts of amine protons observed for 




reacted with DMSO. Therefore, having 4.17 and 4.18 present in solution seems more likely 
than 4.16 and 4.19. 
 
Figure  4-20 a) The 1H NMR spectrum of [(nta)Co(µ-OH)2Pt(NH3)2](4.16) in d
6 DMSO at 25 °C b) The 1H 









Figure  4-21 a) The 1H NMR spectrum of cisplatin instantly after dissolving in d6 DMSO b) 30 min after 
dissolving in d6 DMSO 
 






Scheme  4-7 Suggested mechanism for the substitution of hydroxido bridging ligand by DMSO 
 
4.5 Antitumour activity study 
Complexes 4.7, 4.12 and 4.16 were screened in preliminary studies of in vitro anti-tumour 
activity against a human colon cell line (DLD-1). The solubility of all three complexes was 
very low in DMSO and they precipitated in the cell line media.  Reporting the IC50 values 
without the entire complexes being dissolved has no real meaning, other than providing a 




Despite the precipitation, an IC50 value of the 4.7 was found to be in the range of 2-7 µM in 
DLD-1 cells, though it is likely that it would be lower if the entire sample of the complex was 
in solution. The other complexes had no activity at the concentrations studied. 
 
4.6 Synthesis and crystal structure of [Co(PMIDA)(OH2)2]·H2O (4.20) 
In an effort to synthesise nta-analogus neutral complexes with better solubility, N-
(phosphonomethyl)iminodiacetic acid (PMIDA), has been used as a ligand to coordinate to 
cobalt. By manipulating the pH, the phosphonate group can be protonated or deprotonated 
and change the charge of the complex. A brief synthetic procedure to prepare 




Scheme  4-8 Synthetic procedure to obtain compound 4.20  
 
After reaction for 2 hours, the volume of the reaction was decreased with rotatory 
evaporator and the reaction mixture was left overnight in the fridge. A precipitate came out 
after one day. The precipitate was suspended in water and the temperature was increased 
to 80 °C. H2O2 was added and the reaction was heated for two hours. The reaction mixture 
was cooled down. The crystals were obtained from diffusion of ethanol into the reaction 
mixture. We could not record NMR data for 4.20 presumably because the complex did not 




be because the H2O2 was not new and possibly decomposed. After addition of H2O2 from a 
new bottle, the reaction mixture foamed, but no solid could be collected. 
The crystal structure of 4.20 is shown in Figure 4-24. This compound crystallises in a 
monoclinic crystal system with P21/c space group. Co is octahedrally coordinated to the two 
arms of the tetradentate PMIDA ligand (O2, O6 and N1) and two water molecules (O8, O9) 
and the oxygen atom of another PMIDA ligand (O7). This leads to formation of a 
coordination polymer and the repeating unit is C5O9NPH2Co. 
The packing structure of 4.20 is presented in Figure 4-25. There is a hydrogen bonding 
interaction between the non-coordinated water molecule and the hydrogen atom on O8 
shown in the packing structure (Figure 4-25). Selected bond lengths and angles are shown in 
Tables 4-4 and 4-5. The bond lengths of Co-O2, Co-O6, Co-O7 and Co-N1 are 2.10, 2.13, 2.08 
and 2.23 Å respectively, which is suggestive of a Co(II) complex. 
 
 





Bond length [Å] 
Co1-O6 2.137(6) O1-C2 1.271(9) 
Co1-O8 2.099(6) O3-C4 1.207(10) 
Co1-O2 2.103(6) O4-C4 1.309(10) 
Co1-O9 2.071(6) O2-C2 1.271(9) 
Co1-O7 2.080(6) N1-C1 1.482(10) 
Co1-N1 2.236(6) N1-C3 1.452(10) 
P1-O5 1.557(7) N1-C5 1.500(10) 
P1-O6 1.522(6) C4-C3 1.517(10) 
P1-O7 1.499(6) P1-C5 1.812(8) 
 



















O7-Co1-N1 89.7 (1) 
 












The complexes (4.7, 4.12 and 4.16) precipitate out from the addition of two solutions of 
[Co(nta)(OH)(OH2)]
- and [Pt(L)(OH)2]
2+. Formation of powder inside the reaction is due to the 
formation of neutral dinuclear complexes. Among synthesised complexes, [(nta)Co(µ-
OH)2Pt(chda)] formed immediately after addition of the two precursors. The low solubility 
of the complexes increases the chances of them actually being pure. 
The dinuclear complexes, 4.7, 4.12 and 4.16, were insoluble in most common solvents. This 
limited our ability to characterise the complexes. All complexes were almost insoluble in 
DMSO. In order to obtain NMR data, the temperature was increased to 80 °C. NMR spectra 
for the complexes showed more signals than expected. A key observation is the fact that the 
material stayed dissolved when the mixture is cooled. It means the materials that stayed 
dissolved inside the NMR tubes have different properties and so may well be different 




chemical shifts that appeared for amine groups are also in agreement with having at least 














Chapter 5. Conclusions and Future Prospects 
5.1 Conclusion 
The main goal of this project is to synthesise smart targeted drug delivery systems that 
deliver drugs to cancer cells with better efficacy and lower toxicity levels. As part of this 
goal, this thesis has described synthetic routes to achieve novel heterodinuclear [Co(µ-
OH)Pt] metal complexes.  
In chapter 2, formation of [{Co(µ-OH)n-M}m] complexes (M =metal ions) complexes by the 
reaction between [Co(en)2(OH)(OH2)] and different metal ions was studied using 
13C NMR 
spectroscopy. The conclusion of this study was that the equilibrium between the cis and 
trans isomers of the Co complex shifts toward the cis isomer after addition of diamagnetic 
metal ions. In addition, the elimination of cis peaks in the 13C NMR after the addition of 
paramagnetic metal ions, showed preferential association of those metal ions with the cis 
isomer of the Co complex. 
The 13C NMR studies show that the reaction of [Co(en)2(OH)(OH2)]
2+ complex with Pt2+ and 
Pd2+ species produces several other complexes in addition to the dinuclear complexes  
observed in the solid state[116].  
Chapter 3 focused on the synthesis and characterisation of [Co(µ-OH)2Pt] complexes. 
Formation of [Co(µ-OH)2Pt] complexes has been characterised, following separations on ion 
exchange resins. However, reaction of [Co(en)2(OH)(OH2)]
2+ and [Co(tren)(OH)(OH2)]
2+  




Separation of products using CM sephadex columns was better than other techniques, but 
high purity Co(µ-OH)2Pt complexes could not be obtained. However, we believe that the 
formation of this class of complexes has been confirmed by a combination of good isotopic 
pattern matches with results from mass spectrometry experiments, and an accumulation of 
NMR evidence. 
In addition to the dinuclear complexes reported in this chapter, the novel crystal structure 
of 3.4 shows that more complicated structures are also formed, either in the reaction 
mixture or via subsequent reactions of the dinuclear complexes. The crystal structure of 3.4 
is presented again in Figure 5-1. 
 
 





An important result of this study is that the 1H NMR spectrum of the crystalline material 
(3.4) was different from the bulk material from which the crystals were obtained (third band 
of the column (3.2)). The integration ratios derived from the 1H NMR spectrum of the 
crystals show 2:1 molar ratios of en ligand vs chda ligand from which a ratio of two Pt vs one 
Co is inferred. But 1H NMR spectra of the complete band (3.2) show 1:1 molar ratios of en 
ligand vs chda ligand, from which a ratio of one cobalt vs one platinum is inferred. 
The occasional observation of formation of a yellow powder, either on the column or in 
eluates, is indicative of further reactions occurring. The yellow powder is presumed to be 
some form of Pt(chda) complex, based on NMR studies.  Mass spectrometry results gave 
isotopic patterns that were a good match for [Pt(µ-OH)2Pt] complexes. This evidence and 
other observations suggest the [Co(µ-OH)2Pt] complexes are rather labile, which limited our 
ability to isolate them as pure compounds. The solubility of these complexes appears to be 
reasonably high in water, which maybe why our various efforts to crystallise them did not 
prove successful. 
The problems associated with the synthesis of [Co(µ-OH)2Pt] complexes in chapter 3 
suggested to attempt to synthesise neutral dinuclear complexes. Nitrilotriacetate (nta), as a 
L3- ligand, was chosen for coordination to the Co(III) centre, and with two hydroxido bridging 
ligands between the Co(III) and Pt(II) ions, the overall charge of the resulting complex will 
come to zero, providing the remaining ligands on the Pt(II) centre are neutral. In the 
synthetic method used, dinuclear complexes precipitated out of the reaction. The low 
solubility increases the chances of the [Co(µ-OH)2Pt] complexes actually being pure. The 
elemental analysis results are consistent with the formula of [(nta)Co(µ-OH)2Pt(L)]·2H2O (L = 
chda, en, (NH3)2 for the complexes. The characterisation of these complexes is limited due to 




most common solvents, except for some solubility in DMSO, and even that seemed to be 
due to reaction with the solvent rather than to simple dissolution. NMR studies done at 25 
°C, were unsatisfactory due to the small amounts of the complexes that were present. 
Therefore, the NMR spectra were recorded at 80 °C. The NMR data are consistent with the 
reactivity of [Co(µ-OH)2Pt] complexes with DMSO. This is consistent with the observation 
that the complexes remained dissolved in the DMSO after cooling down to room 
temperature.  
Overalls, results obtained from chapter 3 and 4 are in agreement that [Co(µ-OH)2Pt] 
complexes do form but they are also rather labile, and their solubility profiles were rather 
inconvenient. This lead us to begin attempts to synthesise complexes in which we may be 
able to control the solubility by manipulating the pH, and to design other [Co(µ-OH)2Pt] 
complexes that may have higher stability. These ideas will be elaborated in the future work 
section, below. 
5.2 Future work 
The future work for this project can be taken in two different directions. 
5.2.1 Manipulating the solubility by changing pH 
We may be able to make dinuclear [Co(µ-OH)2Pt] complexes with better control on solubility 
by changing pH. N-(Phosphonomethyl)iminodiacetic acid (PMIDA), shown in Figure 5-2, is a 
ligand analogous to nta, which may be able to coordinate to Co. By manipulating the pH, the 
phosphonate group can be protonated or deprotonated and change the charge of the 
complex. One of our preliminary efforts to synthesise [Co(PMIDA)(OH2)2] is reported in 




reported Co(II) complexes of PMIDA ligand[144],[145],[146],[147],[148],[149]. A method for oxidising 
should be established, possibly by addition of hydrogen peroxide or aeration. Subsequent 
reactions might then be undertaken, using approaches similar to those used for nta 
complexes. 
 
Figure  5-2 Structure of N-(phosphonomethyl)iminodiacetic acid (PMIDA) 
 
5.2.2 Changing the lability of [Co(µ-OH)2Pt] complexes  
A method for preparation of dinuclear [Co(µ-OH)2Pt] complexes, is proposed in Scheme 5-1. 
By following this method, hopefully, the ligand exchange on platinum can be avoided by 
introducing a bulky substitution to the ligand on Co, to block either sides of the platinum. 
1,8-Naphthalimide is the proposed blocking group as it is planar and easily prepared from 
primary amines. 
3,6,9,12-Tetraazatetradecane-1,14-diamine, is commercially available. The dinitro cobalt 
complex can be prepared by air oxidation of Co(NO3)2⋅6H2O with a stoichiometric quantity 
of the ligand and NaNO2
[150]. The diaqua compound can be prepared by a method used for a 
similar complex[151]. 
The difficulty with the suggested reaction would be the fact that the association of the 




mention about the suggested [Co(µ-OH)2Pt] complex, is that the 3+ charge of the complex 
might make the synthesis more complicated, but perhaps the hydrophobic blocking groups 
would favourably affect the solubility of the complex. We also suggest addition of an anionic 
substituent on the bulky groups to produce neutral complexes. 
Once hetero-dinuclear [Co(µ-OH)2Pt] complexes of this kind have been made, in the future, 
then the platinum drug release upon bio-reduction in hypoxic cell will be studied. Scheme 5-
2 proposed the mechanism of action of [Co(µ-OH)2Pt] complexes in the hypoxic region of 





Scheme  5-1 Proposed mechanism to produce stable [Co(µ-OH)2Pt] complexes. The long chain amine 





































Chapter 6. Terpyrine-derived Organotin Complexes  
6.1 Introduction 
Organotin(IV) compounds have received considerable attention in recent years. This interest 
has been due to the remarkable structural diversity present, such as monomers, dimers, 
tetramers, ladders, cubes, butterflies and hexameric drums. Based on the type of organic 
ligands, tin-R groups, tin coordination geometry preferences and metal-to-ligand molar 
ratios, these various organotin derivatives have been constructed.[152],[153],[154],[155],[156],[157] 
Another reason for this interest is due to their significantly important biological activities: 
bactericidal, fungicidal, biocidal and pesticidal. Furthermore, varieties of di- and tri-
organotin species have shown potential as anticancer and anti-tuberculosis 
agents[158],[159],[157],[160],[161]. 
Cisplatin could bind to DNA with an intra-strand or inter-strand cross-link, while 
organotin(IV) compounds bind either to DNA bases or phosphate-oxygens of the DNA 
helix[162]. Different mechanisms of action of organotin compounds lead to alternative 
therapeutic protocols showing advantage in terms of lower toxicity and platinum induced 
resistance[163],[164],[165]. 
Gielen has demonstrated the effects of tin-based antitumour compounds and found that 
the in vitro antitumour activities of some di-n-butyltin, di-t-butyltin and diphenyltin 2,6-
pyridinedicarboxylates were better than that of cisplatin against WiDr (a colon carcinoma) 




donor ligands coordinated to the metal have resulted in several diorganotin(IV) and 
triorganotin(IV) compounds with high in vitro activity[168]. Generally, both diorganotin(IV) 
and triorganotin(IV) compounds could be active, but the activity of triorganotin(IV) 
compounds with a higher partition coefficient value is generally higher than the di- and 
monoanalogues, following the order R3SnL > R2SnL2 > RSnL3
[169],[170]. Activity of organotin(IV) 
compounds was dependent on the R group, and decreased in the order: n-Bu > Ph and Et > 
Me as R[171]. The anti-cancer activity of several organotin compounds against WiDr and MCF-
7 cells by Gielen have demonstrated that the R groups play more important roles than 
ligands, but the ligands (L) also play an important role in the bioactivity[166],[167]. Moreover, 
the studies on structure–activity correlation of organotin(IV) compounds by Huber[172] 
demonstrated that antitumour active organotin compounds should possess available 
coordination positions on the tin atom and also have low hydrolytic cleavage of the Sn-alkyl 
(or Sn-aryl) bonds. However, a necessary balance between lipophilic and hydrophilic 
properties is needed to cross the cell membrane and to demonstrate activity in an aqueous 
environment. It has been established that organotin(IV) compounds are very important in 
cancer chemotherapy because of their apoptosis inducing character[173],[174]. The exact 
mechanism by which organotin compounds exert their anticancer effect is not fully 
understood, but it has been suggested that organotin(IV) compounds could bring about 
numerous cellular effects; inhibition of macromolecular synthesis (DNA and protein 
synthesis), apoptosis by increasing intracellular Ca2+ concentration, followed by reactive 
oxygen species formation and cytochrome-c release from mitochondria, caspase activation 





Organotin compounds are famous for their versatile coordination chemistry that involves 
various coordination modes. The coordination number of tin(IV) varies from 4 to 6 in most 
cases[178]. The coordination number can be as high as 8 if appropriate chelating ligands are 
introduced[179]. 
2,2’:6’,2’’-Terpyridine derivatives are remarkable ligands for almost all the transition metal 
ions through the {N, N, N} coordination mode; some of their complexes have even evaluated 
as antitumour drugs[180]. 
This study is based on the ligands synthesised by a graduated PhD student of our research 
group, Gurpreet Kaur. Kaur synthesised terpyridine-amine based polydentate ligands and 
consequently synthesised a range of mono-, di-, and polynuclear complexes derived from 
them[181]. 
We will discuss the synthesis and characterisation of organotin complexes with 4'-(2"'-
toluyl)-2,2':6',2"-terpyridine (ottp) and 4'-(4"'-toluyl)-2,2':6',2"-terpyridine (pttp) ligands. 
 
6.2 Results and discussion 
6.2.1 Synthesis and characterisation of terpyridine derived organotin complexes 
6.2.1.1 [Sn(CH3)2Cl2(pttp)] 
The synthesis of the ottp ligand using a ‘one pot method’ has been reported in Kaur’s 
thesis[181]. The pttp ligand was synthesised by a similar method. 








Scheme  6-1 Brief description of synthesis of 6.1 
 
The 1H NMR spectrum of 6.1, shown in Figure 6-1, was recorded in d6 DMSO. The 
integrations of the protons on the methyl ligands on Sn, protons on pttp and the aromatic 
ring protons are 6, 3 and 14 respectively. The integrations are consistent with 1:1 metal to 
pttp coordination. The singlet peak at 1.02 ppm is assigned to the methyl protons attached 
to Sn (Figure 6-1). The methyl group signals carry satellites due to coupling of hydrogen 
atoms with 117Sn and 119Sn nuclei which have abundances of 7.68% and 8.59% respectively 
(Figure 6-2). The signals of the aromatic region were fully assigned (Figure 6-1b) using the 1H 
















Figure  6-3 The 1H-1H COSY spectrum of 6.1 (Top), The enlargement of the aromatic region (bottom) 
 
The 13C NMR spectrum of 6.1, in d6 DMSO, contains 1 signal at 20.84, 1 signal at 22.74 and 
11 signals between 117.63 and 155.63 ppm, which we have assigned to the methyl carbon 
atoms on the ligand, methyl carbon atoms on tin and the aromatic rings carbon atoms of 




There are 12 kinds of carbon atoms (7 tertiary and 5 quaternary) in complex 6.1 but 11 
signals appeared. Only 4 quaternary carbon signals appeared while there are 5 of them in 
pttp ligand. The DEPT spectrum demonstrated that one of the quaternary signals is buried 
underneath one other signal at 149.34 ppm (Figure 6-5).  
 
 




Figure  6-5 The DEPT spectrum of 6.1. The red highlight identifies a quaternary carbon atom 




Cross peaks in the COSY spectrum show that H3,3’’ (t) couple to H4,4’’ (d), H4,4’’ couple to 
H5,5’’ (d), and H5,5’’ couples to H6.6’’ (t). There is also a coupling between H3’’’,5’’’ (d) and 
H2’’’,6’’’ (d). The HMBC spectrum shows that there is a coupling between C3’’’,5’’’ and 
methyl group of pttp ligand. Another coupling to the methyl group is seen for C2’’’, C6’’’. 
C1’’’ or C4’’’ couples to H3’’’, 5’’’; and C4’’’ or C1’’’ couples to H2’’’, 6’’’ in the HMBC 
spectrum. The quaternary signal at 134.53 ppm is assigned to C1’’’ as it couples to H3’,5’.  
C3’,5’ couple in the HSQCD spectrum to the singlet assigned to H3’, 5’. H6,6’’ and 
H5.5’’couple to C1,1’’ in the HMBC spectrum. C1,1’’ couple to H3,3’’ and H3’5’ in the HMBC 

















The correlation between C-Sn-C angle and 1J(13C-119Sn) is a useful method for providing 
information about the coordination environment of the tin(IV) nucleus[182]. In particular, the 
magnitude of 1J(13C-119Sn) in solution has been related to the Sn coordination number.  
The coupling constants 1J(13C–119Sn) = 1033 Hz in 6.1 are consistent with a seven-
coordinated methyltin complex[182].  
The Lockhart and Manders equation given below correlates the C-Sn-C bond angle with the 
coupling constant 1J(119Sn-13Cα)
[183]: 
θ = 0.0877 1J(119Sn-13Cα) + 76.7543 
The magnitude of θ calculated from this equation (166˚) for compound 6.1 is comparable to 
that obtained from the X-ray crystallographic data (θ = 164.39°). 
A few X-ray quality crystals, ([Sn(CH3)2Cl(pttp)]·0.5[Sn(CH3)2Cl4].CH2Cl2, (6.2) were obtained 
by slow evaporation of a dichloromethane solution of crude 6.1. The crystal structure of 6.2 
is shown in Figure 6-8. This compound crystallised with one formula unit in the asymmetric 
unit. Sn(IV) is octahedrally coordinated to three N atoms of the pttp ligand, two methyl 
ligands and one chloride ligand. Selected bond length and selected bond angles are 
presented in Tables 6-1 and 6-2. 
A [Sn(CH3)2Cl4]
2− ion is present as a counter ion and half of this moiety is present in the 
asymmetric unit. As the oxidation state of tin is IV, the methyl group is considered to be a −1 
ligand. The charge of the [Sn(CH3)2Cl(pttp)] moiety is +1. The packing diagram of 6.2 is 





Figure  6-8 The crystal structure of [Sn(CH3)2Cl(pttp)]·0.5[Sn(CH3)2Cl4].CH2Cl2 (6.2), with hydrogen 
atoms and one DCM molecule omitted for clarity 
 
 



















Selected bond angles [°] 
Cl2-Sn2-Cl3 89.86(4) C24-Sn1-Cl1 84.98(15) 
C25-Sn2-Cl3   89.27(14) C24-Sn1-N2 92.81(18) 
C25-Sn2-Cl2   92.27(14) C24-Sn1-N3 98.93(18) 
N2-Sn1-Cl1 164.37(11) C24-Sn1-N1 85.78(18) 
N2-Sn1-N1 68.92(15) C24-Sn1-C23 164.4(2) 
N3-Sn1-Cl1 93.43(11) C6-N2-Sn1 122.2(3) 
N3-Sn1-N2 71.59(15) C16-N2-Sn1 118.7(3) 
N3-Sn1-N1 140.41(15) C16-N2-C6 119.0(4) 
N1-Sn1-Cl1 126.16(11) C17-N3-Sn1 118.3(3) 
C23-Sn1-Cl1 88.50(15) C21-N3-Sn1 121.6(3) 
C23-Sn1-N2 97.18(18) C21-N3-C17 120.0(4) 
C23-Sn1-N3 95.60(17) C5-N1-Sn1 117.4(3) 
C23-Sn1-N1 86.66(17) C1-N1-Sn1 123.2(3) 
 
Table  6-2 Selected bond angles for structure of [Sn(CH3)2Cl(pttp)]·0.5[Sn(CH3)2Cl4].CH2Cl2 (6.2) 
 
Figure  6-9 packing diagram of [Sn(CH3)2Cl(pttp)]·0.5[Sn(CH3)2Cl4].CH2Cl2 (6.2) 
 
In order to check that the single crystal is representative of the bulk sample, the X-ray 
powder diffraction (PXRD) patterns were recorded.  As shown in Figure 6-10, the peak 
positions in the calculated and experimental patterns are not in good agreement with each 




obtained by NMR confirm that the bulk material is largely different from that in the single 




Figure  6-10 Calculated powder pattern from the single crystal structure solution, 6.2 (red), and 
Experimental PXRD pattern for the bulk sample, 6.1 (blue)  
 
The mass spectrum of 6.1 contained peaks at m/z = 541.97 which can be assigned to the  
[M-H+]1-  ion (Figure 6-11).   
In summary, mass spectrum and NMR data obtained from coupling constant (1J(13C–119Sn)) 
are in agreement with having seven coordinated tin complex. However, the crystal structure 



















Figure  6-11 Experimental (top) and simulated isotope patterns for the highest abundance mass peak 




The synthesis of [Sn(CH3)2Cl(ottp)]Cl (6.3) is presented below in Scheme 6-2. 
 
 





The 1H NMR spectrum of [Sn(CH3)2Cl(ottp)]




Figure  6-12 The 1H NMR spectrum of 6.3 in CDCl3 
 
The integration ratios of the aromatic ring proton, methyl proton on ottp ligand and the 
protons on the methyl ligands are 12:3:6 representing coordination of 1 equivalent of ottp 
to 1 equivalent of Sn, and two methyl ligands on Sn.  
The singlet peak at 1.19 ppm in the 1H NMR spectrum of [Sn(CH3)2Cl(ottp) ]
+ is assigned to 
the methyl protons attached to Sn. The methyl group signals carry satellites due to coupling 
of hydrogen atoms with 117Sn and 119Sn nuclei. 
Some of the aromatic protons signals are readily assigned using the 1H-1H COSY spectrum 
(Figure 6-13). H3,3’’ (d) couple to H4,4’’(t); H4,4’’ (t)couple to H5,5’’ (t); and H5,5’’ (t) couple 





Figure  6-13 The 1H-1H COSY spectrum of 6.3 
 
The 13C NMR spectrum of 6.3, shown in Figure 6-14, is fully assigned using HSQCD, HMBC 
and DEPT NMR studies. The two peaks at 17.87 and 20.47 ppm are assigned to carbon 







Figure  6-14 a) The 13C NMR spectrum of 6.3 in CDCl3 b) An enlargement of the aromatic region 
 
Tertiary and quaternary carbon atoms were recognised by DEPT spectrum (Figure 6-15). 
The tertiary carbon atoms, except those in the toluyl ring, were assigned by using HSQCD 









Figure  6-16 The 1H-13C HSQCD spectrum of 6.3. The red lines show the coupling between 1H and 13C 
nuclei of the toluyl ring. The blue lines show the coupling for the rest of the ligand 
 
The quaternary carbon atoms and the toluyl ring were assigned by using HMBC spectrum 
(Figure 6-17). The quaternary signal at 154.72 ppm has a cross peak with the doublet of a 




hydrogen signal at 7.43 ppm is assigned to 6’’’. The signal at 129.46 ppm is assigned to C6’’’ 
from the HSQCD spectrum.  C1’’’ couples to H3’5’ and the multiplet of the toluyl ring. C2’’’ 
couples to the multiplet and the doublet of the toluyl ring as well as the methyl group in the 
HMBC spectrum. The signal at 129.23 ppm does not have any coupling with a methyl group; 
therefore it is expected to be C5’’’. The signal at 130.87 ppm is assigned to C3’’’ as it has a 
strong coupling with the methyl protons and the multiplet of the toluyl ring. The signal at 
126.37 ppm is assigned to C4’’’ since the coupling with the methyl is much weaker. 
The signal at 152.08 ppm is assigned to C1,1’’ as they have coupling with H3,3’’ and H 5,5’’ in 
HMBC spectrum. The signal at 152.31 ppm is assigned to C2’,6’ as they have coupling with 










The coupling constants 1J(13C–119Sn) = 801.86 Hz in 6.3 suggest a six-coordinated dimethyltin 
complex[182].  
The Lockhart and Manders equation given below correlates the C-Sn-C bond angle with the 
coupling constant 1J(119Sn-13Cα). 
θ = 0.0877 1J(119Sn-13Cα) + 76.7543 
The magnitude of θ calculated from this equation is 147° for compound 6.3. 
Results from elemental analysis were consistent with the formula of [Sn(CH3)2Cl(ottp)]Cl. 
We considered one chloride attached to Sn and another as the counter-ion due to the 
coordination number of Sn found by NMR results. 
The mass spectrum of 6.3 was taken in ethanol, and the whole molecular mass peak was not 
found. But the mass peak found in m/z 518.12 is a good match with the formula of                     
[Sn(CH3)2(OEt)(ottp)]
1+ (Figure 6-18). Thus it appears that before or during the mass 










6.2.1.2 [SnCl2(ottp)(Ph)][SnCl2(Ph)3]  









A pure sample of the titled complex was not isolated; however, the single crystal diffraction 
defined the structure as shown in Figure 6-19. X-ray quality crystals were obtained by 
diffusion of diethyl ether into the dichloromethane solution of crude 6.4. 
There are only a few crystal of 6.4 obtained. 
 
Figure  6-19 Crystal structure of 6.4. The crystal is disordered based on coordination around Sn2 and 
the phenyl ring attached to Sn1. The phenyl ring attached to Sn2 showed disorder with 66% 
occupation and the chloride atom shown in pink occupied 33%. The occupation of the atoms shown 
in pink is 33% 
 
Sn1 is octahedrally attached to three nitrogen atoms of the ottp ligand, two chloride ligands 
and a phenyl ring. This unit formed a +1 complex. The counter-ion of this complex is a five 
coordinate tin complex. The Coordination around Sn1 is disordered in which the ligands are 




The selected bond lengths and bond angles of 6.4 are shown in Tables 6-3 and 6-4. The 


























Table  6-4 Selected bond angles for 6.4 
Bond length [Å] 
Sn2-Cl4 2.516(2) 

















Figure  6-20 The packing diagram of 6.4 
 
6.2.1.3 [SnCl2(Ph)(pttp)][SnCl2(ph)3] (6.5) 
The synthesis of [SnCl2(Ph)(pttp)][SnCl2(Ph)3] (6.5) is presented below in Scheme 6-4. 
Unfortunately, X-ray quality crystals could not be obtained. However, results from 
elemental analysis were consistent with the formula of [Cl2(ph)Sn(pttp)][(ph)3SnCl2] which is 
suggested to have a structure similar to 6.4. 
 
 





The 1H NMR spectrum of 6.5 is shown in Figure 6-18. The integration ratio of the pttp ligand 
protons vs phenyl rings protons on Sn is 14 to 20, which is in agreement with the structure 
defined for 6.5. The protons on the pttp ligand are assigned as shown in Figure 6-21.  
 
 
Figure  6-21top: The 1H NMR spectrum of 6.5 (top) in DMSO, The enlargement of the aromatic 






The 13C NMR spectrum of 6.5 is shown in Figure 6-22. The signal at 20.82 ppm is assigned to 
methyl carbon atom on pttp ligand. The aromatic region signals are assigned based on the 
assignments of 6.1. The signals marked by stars are assigned to phenyl carbon atoms on Sn. 
There are 7 quaternary and 13 tertiary kinds of aromatic carbon atoms in 6.5. There are 16 
signals in the aromatic region. The DEPT spectrum showed there is a quaternary signal 
underneath the tertiary signal at 149.34 ppm (Figure 6-23). The DEPT spectrum shows 5 
kind of quaternary signals while there are 7 of them in the proposed structure. The two 
signals at 154.99 and 155.65 ppm are twice as tall as other quaternary signals. Thus, we 






Figure  6-22 The 13C NMR spectrum of 6.5 (Top).  The enlargement of the aromatic region (bottom). 





Figure  6-23 The DEPT NMR spectrum of 6.5. the red highlight identifies a quaternary carbon atom 
appeared in same chemical shift with a tertiary carbon atom 
 
The 1H-13C HSQCD NMR spectrum of 6.5 showed the signal at 134.68 ppm has a correlation 
with H5,5’’ of the ligand and the protons of the phenyl ring on Sn (Figure 6-24). This 
represents two different kinds of signals appearing in a same place in 134.68 ppm. 
 
 




The positive ion mass spectrum did not show any peaks matching with 6.5. The negative ion 
mass spectrum of 6.5 is shown in Figure 6-25. The enlargement of the mass peaks at m/z:  
378.85 and 420.91 and their simulations are shown in Figure 6-26.  
 
 
Figure  6-25  Mass spectrum of 6.5 and the enlargement of the main peaks (Top), and the 
enlargement (bottom) 
 









Figure  6-26 The enlargement of the main peaks in the mass spectrum of 6.5. a) Experimental (top) 
and simulated isotope patterns for the mass peak of [SnCl3(ph)2]
1- ion b) Experimental (top) and 
simulated isotope patterns for the mass peak of [SnCl2(ph)3]






In this chapter, the syntheses and characterisation of organotin complexes with terpyridine 
based ligands were discussed. The structure obtained from X-ray diffraction experiments on 
single crystals did not match with data obtained from NMR and mass spectra for 6.1. NMR 
and mass studies are in agreement with having a 7-coordinated tin complex 
([Sn(CH3)2Cl2(pttp)]) while a crystal structure showed a 6-coordinated organotin complex 
with a six-coordinated organotin complex as a counter-ion [Sn(CH3)2Cl(pttp)]-
·0.5[Sn(CH3)2Cl4].CH2Cl2 (6.2). 
We considered one of the chloride atoms as a counter-ion since data obtained from 
coupling constants in 6.3 led us to suggest a 6-coordinate organotin complex is formed. 
Moreover, the mass peak found in the mass spectrum of 6.3 was consistent with a 6-
coordinated tin complex with the formula of [(EtOH)(CH3)2Sn(pttp)]
+. Presumably, the 
chloride was replaced by the sample solvent (ethanol). 
The pure complex, [SnCl2(ph)(ottp)][SnCl3(ph)3], was not isolated from the reaction between 
SnCl2(ph)2 and ottp. However, the a crystal structure of a single crystal is shown in Figure 6-
27. 
 





We did not obtain a crystal of 6.5 for diffraction but elemental analysis and NMR data are in 

















Chapter 7. Experimental 
 
7.1 General Information 
All solvents, reagents and starting materials were reagent grade, purchased from standard 
suppliers and used without purification. Solvents used for syntheses of complexes were 
analytical grade and used as received. Water was purified in-house by reverse osmosis. All 
anhydrous solvents used in reactions of moisture sensitive compounds were purified either 
in-house by passing over a sealed column of activated alumina or distilled from standard 
drying agents. Electro-thermal Melting Point Apparatus used to record melting points. 
Microanalyses were performed by Campbell Microanalytical Laboratory at the University of 
Otago, New Zealand. 
 
Nuclear Magnetic Resonance 
1H and 13C NMR spectra were recorded on Varian VNMR 500, or Agilent 400MR with Varian 
7600-AS auto-sampler. Spectral chemical shifts were referenced to the residual solvent 
resonance or, in the case of D2O, using TPMS or dioxane as an internal reference. 2D COSY, 
HSQCD, HMBC and DEPT experiments were performed to assign proton and carbon peaks 
where required, using standard Varian pulse sequence. All samples were prepared in 








Mass spectra were recorded by Dr. Marie Squire and Dr. Amelia Albrett on a BrukerMaXis4G 
spectrometer. The instrument was operated in a high resolution positive and negative ions 
electron spray mode. Samples were prepared by dissolving and diluting to the required 
concentration in appropriate HPLC grade solvents. 
 
Infrared Spectroscopy 
Infrared spectra were recorded on a Bruker FTIR spectrometer equipped with Alpha’s 
Platinum ATR single reflection diamond, and samples were placed directly on the diamond 
under clamp without any preparation (denoted neat). The abbreviations used are: s: strong, 
vs: very strong, m: medium, w: weak, sh: sharp. 
 
X-Ray Crystallography 
X-ray data were collected on an Oxford-Agilent Supernova instrument with a focused 
microsource Mo Kα [λ = 0.71073 Å] or Cu Kα [λ = 1.54184 Å] radiation and an ATLAS CCD 
area detector. CrysAlisPro 171.36.28 was used for the data collection and data processing. 
The crystals were mounted on nylon loop using a perfluorinated polyethylene glycol. The 
crystal was kept at 120.00(10) K during data collection. All structures were solved using 
direct methods with SHELXT and refined on wF2 using all data by full matrix least square 
procedures with SHELXL using OLEX-2 for visualisation. Graphical presentation of 
crystallographic data was prepared using OLEX-2 and the Graphical presentation of lattice 






Synthesis of precursors and ligands 







[187], pttp[181], ottp[181]. 
 
7.2 Experimental related to chapter 2 
7.2.1 Study of reaction of [Co(en)2(OH)(OH2)](ClO4)2 with different diamagnetic metals 
Each titration was carried out inside a 5 mm NMR tube, with [Co(en)2(OH)(OH2)](ClO4)2 
(0.0860 g, 1 eq) and different molar equivalents of M (M= Li(NO3), K(NO3), Mg(NO3)2, 
Ag(NO3), Zn(ClO4)2,  Zn(NO3)2, Cd(NO3)2, K2[PdCl4] and K2[PtCl4]) in 1 ml D2O).  TMPS (3-
(trimethylsilyl)-1-propanesulfonic acid) was added inside the tube as an internal reference. 
The 13C-NMR spectrum was taken 30 minutes after addition of the M to cobalt complex 
solution. 
 
7.2.2 Study of reaction of [Co(en)2(OH)(OH2)](ClO4)2 with different paramagnetic metals 
Each titration was carried out inside a NMR tube between [Co(en)2(OH)(OH2)](ClO4)2 (0.0860 
g, 1 eq) and different molar equivalents of M (M= Cu(NO3)2, Ni(NO3)2 and Fe(NO3)3 in 1 ml 
D2O).  1,4-Dioxane was used as an internal reference to compare the integrations with. The 







7.3 Synthesis of chapter 3 compounds 
7.3.1  [(en)2Co(µ-OH)2Pt(chda)]
3+, 3.2 
Silver nitrate (0.60 g, 3.54 mmol) was 
added to [Pt(chda)I2] (1.00 g, 1.77 
mmol) in 5 ml water. The reaction 
mixture was stirred for 2 days in dark. 
Silver iodide precipitate was centrifuged 
and supernatant was added to 
[Co(en)2(OH)(OH2)](ClO4)2 (0.73 g, 1.77 mmol) in water. The reaction mixture was stirred for 
3 days. The reaction mixture was filtered and the filtrate was evaporated to dryness to give 
reddish oil.  
The crude compound was purified using cation exchange chromatography on CM Sephadex. 
The third band eluted with 0.4 M NaNO3 solution was collected and evaporated to dryness. 
Most of the salt was removed by few methanolic extractions followed by G10 size exclusion 
column chromatography. Characterisation was done on red slurry obtained after solvent 
evaporation. Small amount of salt was remained, which limited the full characterisan. Due 
to remaining of some amount of salt determination of the yield was not possible. 
1H NMR: (400 MHz, D2O), δ 3.17 (m, 2H, Ha,Hd), 3.03 (m, 2H, Ha’,Hd’), 2.62 (m, 2H, Hb,Hc), 
2.56 (m, 2H, Hb’,Hc’), 3.17 (m, 2H, Ha,Hd), 2.26 (m, 2H, H1,H2), 2.05 (m, 2H, H6’,H3’), 1.60 
(m, 2H, H4,H5), 1.29 (m, 2H, H3,H6), 1.19 (m, 2H, Ha4’,H5’) 13C NMR: (400 MHz, D2O), δ 
62.08 (C1, C2), 44.69, 43.63 (C1, C2, C3, C4), 31.58 (C3, C6), 23.89 (C4, C5). ESI-MS: (water): 
m/z ([(en)2Co(µ-OH)2Pt(chda)-2H







3+, 3.5  
Silver nitrate (1.12 g, 6.66 mmol) was 
added to cisplatin (1.00 g, 3.33 mmol) in 5 
ml water. The reaction mixture was 
stirred for 2 days in dark. Silver chloride 
precipitate was centrifuged and the 
supernatant was added to 
[Co(en)2(OH)(OH2)] (ClO4)2  (1.37 g, 3.33 mmol) in water. The reaction mixture was stirred 
for 3 days. The reaction mixture was attempted to be isolated by G10 size exclusion column 
chromatography but it did not work. The characterisation was done on the red slurry 
obtained after solvent evaporation of the reaction mixture.  
1HNMR: (400 MHz, D2O), δ 3.00, 2.91, 2.60 (m, m, m, 4H, Ha,Hb,Hc,Hd). 
13C NMR: (400 MHz, 





3+, 3.6  
Silver nitrate (1.12 g, 6.66 mmol) was added 
to cisplatin (1 g, 3.33 mmol) in 5 ml water. 
The reaction mixture was stirred for 2 days in 
dark. Silver chloride precipitate was 
centrifuged and supernatant was added to 
[Co(tren)(OH)(OH2)](ClO4)2 (1.45 g, 3.33 mmol) in water. The reaction mixture was heated 






The reaction mixture was filtered and the filtrate was evaporated to dryness to give reddish 
oil. The crude material was diluted in minimum amount of water and the mixture separated 
using size exclusion column chromatography on Sephadex G10 resin (30⨯1.5). [(en)2Co(µ-
OH)2Pt(NH3)](NO3)3 was collected from the second band and [(en)2Co(µ-OH)2Pt(NH3)2](ClO4)3 
was collected from the second band. 
1HNMR: (400 MHz, D2O), δ 3.16, 3.04 (m, m, 4H, Ha,Ha’,Hf,Hf’), 2.64, 2.18 (m, d, 4H, 
Hb,Hb’,Hc,Hc’), 2.62 (t, 2H, Hc,Hc’), 2.35 (t, 2H, Hd, Hd’). 13C NMR: (400 MHz, D2O), δ 60.40 













Silver nitrate (0.60 g, 3.54 mmol) was added 
to [Pt(chda)I2] (1.00 g, 1.77 mmol) in 5 ml 
water. The reaction mixture was stirred for 
2 days in dark. Silver iodide precipitate was 
centrifuged and supernatant was added to 
[Co(tren)(OH)(OH2)](ClO4)2 (0.77 g, 1.77 mmol) in water. The reaction mixture was heated 
for overall 2 hours in a microwave (450 W) with 90 sec intervals. 
The crude compound was purified using cation exchange chromatography on CM Sephadex. 





Characterisation was done after removing the salt by methanolic extractions followed by 
G10 size exclusion column chromatography.  
1H NMR: (400 MHz, D2O), δ 3.60, 3.51 (m, m, 4H, Ha,Ha’,Hf,Hf’), 3.09, 2.61 (m, d, 4H, 
Hb,Hb’,Hc,Hc’), 3.05 (t, 2H, Hc,Hc’), 2.80 (t, 2H, Hd,Hd’), 2.23 (m, 2H, H1,H2), 2.00 (m, 2H, 
H3’,H6’), 1.55 (m, 2H, H4,H5), 1.24 (m, 2H, H3,H6), 1.12(m, 2H, H2’,H5’). 13C NMR: (400 
MHz, D2O), δ 62.22 (C1, C2), 62.97 (Cb,Ce), 59.77 (Cc), 44.83 (Ca, Cf), 44.27 (Cd), 31.69 (C6, 
C3), 24.02 (C4, C5). ESI-MS: (water): m/z [(tren)Co(µ-OH)2Pt(chda)-H
+)]2+ 273.08. 
 
7.4 Synthesis of chapter 4 compounds 
7.4.1 [Co(nta)(OH2)2], 4.1 
Cobalt(II) chloride hexahydrate (5 g, 38.5 mmol) was added to a solution of nitrilotriacetic 
acid (nta) (4.7 g, 38.5 mmol) in potassium bicarbonate (0.2 M, 25 mL). The reaction mixture 
was heated at 70˚ C for an hour.  Hydrogen peroxide (50%, 1 mL) was added and the 
reaction was stirred for half an hour at 70˚ C. The mixture was left in the fridge overnight. 
The resulting precipitate was then filtered and washed with ethanol and diethyl ether. The 
product was obtained by recrystallisation of the powder from hot water. Yield: 22%. 
1H NMR: (500 MHz; solvent D2O) δ 4.13 d(AB), 4.36 d(AB)  






7.4.2 [(nta)Co(OH)2Pt(chda)], 4.7  
[Pt(chda)I2] (597 mg, 1.06 mmol) was 
treated with silver nitrate (360 mg, 2.12 
mmol) in 2 mL of water for two days. The 
silver iodide precipitate was centrifuged 
and the supernatant was separated. The 
pH of the supernatant was adjusted to 5 
by addition of NaOH solution. [Co(nta)(OH2)2] (300 mg, 1.06 mmol) was suspended in 4 mL 
of water and the pH was adjusted to 5.15 by addition of NaOH solution. The platinum 
supernatant was added to cobalt solution. The reaction mixture was stirred for 18 h. The 
precipitate was collected and washed with ethanol and diethyl ether. Yield: 550 mg 90%, 
M.p: Stable over 250 °C 
Elemental Analysis: Found C 23.28, H 4.45, N 6.58, Calcd. ([Co(nta)(OH)2Pt(NH3)2]·2H2O) (%): 
C 23.00, H 4.19, N 6.71. IR: υmax 3401(w), 3196(w), 2940(w), 1621(vs), 1372(s), 951(m), 
926(m), 490(m) cm-1. 
 
7.4.3 [Co(nta)(OH)2Pt(en)], 4.12 
 Dichlorido(ethane-1,2-diamine)platinum(II) 
([PtCl2(en)]) (345 mg, 1.06 mmol) was treated 
with silver nitrate (359 mg, 2.12 mmol) in 2 ml 
of water for two days. The silver chloride 
precipitate was centrifuged and the 






NaOH solution. [Co(nta)(OH2)2] (300 mg, 1.06 mmol) was suspended in 4 ml of water and 
the pH was adjusted to 5.15 by addition of NaOH solution. The platinum supernatant was 
added to cobalt solution. The reaction mixture was stirred for 18 h. The precipitate was 
collected and washed with ethanol and diethyl ether. Yield: 473 mg 85%, M.p: Stable over 
250 °C 
 Elemental analysis: Found C 16.87, H 3.28, N 7.06, Calcd. ([Co(nta)(OH)2Pt(en)].2H2O) (%): C 
16.78, H 3.52, N 7.34. IR: υmax 3229(w), 3095(w), 2985(w), 1614(vs), 1446(w), 1364(s), 
1217(m), 928(w), (896(w), 463(sh), 450(sh) cm-1. 
 
7.4.4 [(nta)Co(OH)2Pt(NH3)2], 4.16 
 
 Cisplatin (318 mg, 1.06 mmol) was treated with 
silver nitrate (350 mg, 2.12 mmol) in 2 ml of 
water for two days. The silver chloride precipitate 
was centrifuged and the supernatant was 
separated. The pH of the supernatant was 
adjusted to 5 by addition of NaOH solution. [Co(nta)(OH2)2] (300 mg, 1.06 mmol) was 
suspended in 4 mL of water and the pH was adjusted to 5.15 using NaOH solution. The 
platinum supernatant was added to the cobalt solution. The reaction mixture was stirred for 
18 h. The precipitate was collected and washed with ethanol and diethyl ether. Yield: 480 
mg 93%, M.p: Stable over 250 °C 
IR: υmax 3279(m), 1621(vs), 1367(m), 1284(w), 928(w), 921(w), 490(m) cm
-1. 
Elemental analysis: Found C 13.67, H 3.32, N 7.94, Calcd. ([Co(nta)(OH)2Pt(NH3)2].2H2O) (%): 





7.4.5 NMR study of [(nta)Co(OH)2Pt(L)] complexes 
The NMR samples of complexes 4.7, 4.12 and 4.16 were prepared in d6 DMSO. The 
complexes were almost non-soluble in DMSO in room temperature. The temperature of the 
NMR machine was increased to 80 °C to increase the solubility of the samples. Results 
obtained from NMR data showed the solubility of the complexes is due to a reaction with 
DMSO. The NMR results of these complexes are fully discussed in chapter 4. 
 
 
7.5 Synthesis of chapter 6 compounds 
 
7.5.1 [Sn(CH3)2Cl2(pttp)], 6.1 
Dimethyltin dichloride (114 mg, 0.52 mmol) was 
added to a 100 mL round bottom flask containing 
pttp ligand (168 mg, 0.52 mmol) in 30 mL dry 
DCM while flushing under N2. The reaction 
mixture was heated at reflux for 6 h. The solvent 
was removed by rotary evaporation. The 
compound was recrystallised from methanol. The 
crystals were filtered and washed with diethyl 
ether. Yield: 240 mg, 78%. M.p: 161 °C 
1H NMR (400 MHz; solvent d6 DMSO): δ 8.75 (2H, d, H6, H6’’), 8.67 (2H, s, H3’, H5’), 8.65 
(2H, d, H3, H3’’), 8.02 (2H, t, H5, H5’’), 7.80 (2H, d, H2’’’, H6’’’), 7.51 (2H, t, H4, H4’’), 7.38 





δ 155.63 (2C, C2’, C6’), 155.98 (2C, C1, C1’’), 149.34 (3C, C3, C3’’, C4’), 139.22 (1C, C4’’’), 
137.46 (2C, C5, C5’’), 134.53 (1C, C1’’’), 130.01 (2C, C3’’’, C5’’’), 128.12 (2C, C2’’’, C6’’’), 
124.51 (2C, C4, C4’’), 120.93 (2C, C6, C6’’), 117.63 (2C, C3’, C5’), 22.74 (1C, C7), 20.84 (C, C8). 
ESI-Ms (MeOH): m/z [Cl2(CH3)2Sn(pttp)-H
+]-  541.97. Elemental analysis: Found (%) C 53.30, 
H 4.30, N 7.50, Calcd. [Sn(CH3)2Cl2(pttp)] (%): C 53.08, H 4.27, N 7.74. IR: υmax 3056(w), 
2915(w), 1601(m), 1582(m), 1465(m), 1427(m), 1252(w), 1194(w), 1017(m) 889(w), 788 (vs), 
742(m), 725(m), 621.69(m) cm-1. 
 
7.5.2 [Sn(CH3)2Cl(ottp)]Cl, 6.3   
 Dimethyltin dichloride (114 mg, 0.52 mmol) 
was added to a 100 mL round bottom flask 
containg ottp ligand (168 mg, 0.52 mmol) in 
30 mL dry DCM while flushing under N2. The 
reaction mixture was heated at reflux for 6 
h. The solvent was removed by rotary 
evaporation. The compound was 
recrystallised from methanol. The crystals 
were filtered and washed with diethyl ether. 
Yield: 190 mg,  70%. M.p: 139 °C 
1H NMR (400 MHz; solvent d6 DMSO): δ 9.04 (2H, d, H3, H3’’), 8.70 (2H, d, H6’, H6’), 8.52 
(2H, s, H3’, H5’), 8.11 (2H, t, H5, H5’’), 7.57 (2H, t, H4, H4’’), 7.44-7.32 (4H, m, H3’’’, H4’’’, 
H5’’’, H6’’’), 2.42 (3H, s, H7), 1.19 (6H, s, H8). 13C NMR (400 MHz; solvent d6 DMSO): δ 





C5, C4’’), 137.95 (1C, C1’’’), 135.09 (1C, C2’’’), 130.87 (1C, C3’’’), 129.46 (1C, C6’’’), 129.23 
(1C, C5’’’), 126.37 (1C, C4’’’), 125.64 (2C, C4, C’’), 123.30 (2C, C3’. C5’), 122.97 (2C, C6, C6’’), 
20.47 (1C, C7), 17.87 (1C, C8). ESI-Ms (EtOH): m/z [Sn(CH3)2(OEt)(ottp)]
+  541.97. Elemental 
analysis: Found (%) C 53.30, H 4.37, N 7.56, Calcd. [Sn(CH3)2Cl(ottp)]Cl (%): C 53.08, H 4.27, 
N 7.74. IR: υmax 3007(w), 2918(w), 1598(m), 1583(m), 1567(m), 1540(m), 1462(m), 1414(m), 
1390(m), 1304(m), 1248(w), 1163(w), 1017(m), 990(w), 893(w), 787(vs), 770(vs), 741(vs), 






Diphenyltin dichloride (233 mg, 0.72 
mmol) was added to a 100 mL round 
bottom flask containg pttp ligand (248 
mg, 0.72 mmol) in 30 mL dry DCM 
while flushing under N2. The reaction 
mixture was heated at reflux for 12 h. 
The solvent was removed by rotary evaporation. The compound was recrystallised from 
methanol. The crystals were filtered and washed with diethyl ether. Yield:  310 mg, 42%, M. 
p: 208 °C 
1H NMR (400 MHz; solvent d6 DMSO): δ 8.77 (2H, d, H3, H3’’), 8.70 (2H, s, H3’, H5’), 8.67 





(1H,d), 7.53 (2H, t, H4, H4’’), 7.40 (2H, d, H3’’’, H5’’’) 7.37-7.28 (12H, m) 2.40 (3H, s, H7), 
1.19 13C NMR (400 MHz; solvent d6 DMSO): δ 155.65 (3C, C2’, C6’, Cph), 154.99 (3C, C1’, C1’’, 
Cph), 149.34 (3C, C3, C3’’, C4), 139.21 (1C, C4’’’), 137.45 (Cph), 134.68 (2C, C5, C5’’), 130.00 
(2C, C3’’’, C5’’’), 127.77 (Cph), 127.28 (Cph), 126.72 (2C, C2’’’, C6’’’), 124.50 (2C, C4, C4’’), 
120.91 (2C, C6’. C6’’), 117.63.97 (2C, C3’, C5’), 20.82 (1C, C7). ESI-Ms (MeOH): m/z 
[SnCl3(ph)2]
-  420.96, [SnCl2(ph)3]
-  378.88.  Elemental analysis: Found C 54.79, H 3.75, N 
4.24, Calcd. [SnCl2(ph)(pttp)][SnCl2(ph)3] (%): C 54.65, H 3.69, N 4.16. IR: υmax 3048(w), 
1599(vs), 1570(m), 1543(m), 1480(sh), 1430(sh), 1405(m), 1367(w), 1306(w), 1256(m), 
1018(sh), 996(m), 891(w), 883(w), 845(sh), 789(vs), 770(vs), 739(sh), 729(vs), 694(vs), 































Two sets of data: A and B 
A  {A1, A2, A3 …AnA} 
























Central limit theorem: 
67% chance that true mean is within ℇ𝐴  ✓ 
95% chance that true mean is within 2ℇ𝐴 
99.5% chance that true mean is within 3ℇ𝐴 
 
Reported value is: 
< 𝐴 > =  ?̅? ± ℇ𝐴 




< 𝑆 > = < 𝐴 > ±< 𝐵 > =  𝑆̅ ± ℇ𝑆 
𝑆̅ = ?̅? ± ?̅? 
ℇ𝑆 = √(ℇ𝐴)2 + (ℇ𝐵)2 
 
Product: 
< 𝑃 > = < 𝐴 >×< 𝐵 >= ?̅? ± ℇ𝑃 
































Appendix 2. Crystallography Tables 
 
A suitable crystal was selected and mounted on a SuperNova, Dual, Cu/Mo at zero, Atlas diffractometer. The crystal was kept at 120.01(10) K 
during data collection. Using Olex2, the structure was solved with the shleXT structure solution program using Direct Methods refined with the 

























Crystal data and structure refinement for crystals in chapter 3   
Identification code 3.3 3.4 3.8 
Empirical formula C5H16CoN5O6  C16H44CoN11O14.9Pt2 C8H22CoN8O9 
Formula weight 301.16 1078.05 433.26 
Temperature/K 120.00(10) 120.01(10) 120.00(10) 
Crystal system monoclinic monoclinic orthorhombic 
Space group P21/c P21/c Pnma 
a/Å 11.3918(7) 15.6651(5) 25.6797(13) 
b/Å 8.4058(5) 11.4383(3) 7.2533(3) 
c/Å 23.4969(12) 21.0628(6) 7.8776(5) 
α/° 90 90 90 
β/° 96.826(5) 106.022(3) 90 
γ/° 90 90 90 
Volume/Å3 2234.0(2) 3627.45(19) 1467.30(13) 
Z 8 4 4 
ρcalcg/cm
3 1.791 1.974 1.961 
μ/mm-1 12.372 18.316 9.883 
F(000) 1248.0 2077.0 900.0 
Crystal size/mm3 0.094 × 0.0143 × 0.0077 0.1152 × 0.0379 × 0.0137 0.1552 × 0.0302 × 0.0117 
Radiation CuKα (λ = 1.54184) CuKα (λ = 1.54184) CuKα (λ = 1.54184) 
2Θ range for data collection/° 7.578 to 153.556 5.87 to 152.884 6.884 to 176.988 
Index ranges -11 ≤ h ≤ 13, -10 ≤ k ≤ 10, -29 ≤ l ≤ 29 -18 ≤ h ≤ 19, -14 ≤ k ≤ 14, -26 ≤ l ≤ 20 -32 ≤ h ≤ 27, -9 ≤ k ≤ 8, -9 ≤ l ≤ 4 
Reflections collected 10974 19930 4109 
Independent reflections 4525 [Rint = 0.0941, Rsigma = 0.1164] 7528 [Rint = 0.0656, Rsigma = 0.0721] 1581 [Rint = 0.0569, Rsigma = 0.0595] 
Data/restraints/parameters 4525/0/307 7528/0/440 1581/0/136 
Goodness-of-fit on F2 1.220 1.161 1.076 
Final R indexes [I>=2σ (I)] R1 = 0.0657, wR2 = 0.1414 R1 = 0.0668, wR2 = 0.1751 R1 = 0.0881, wR2 = 0.2457 
Final R indexes [all data] R1 = 0.1078, wR2 = 0.1591 R1 = 0.0847, wR2 = 0.1938 R1 = 0.0995, wR2 = 0.2597 





Crystal data and structure refinement for crystals in chapter 4 
Identification code 4.2 4.6 4.20 
Empirical formula C12H28Co2K2N2O27 C12H29.8Co2.5N2O21.4 C5H15CoNO10P 
Formula weight 828.42 691.90 339.08 
Temperature/K 120.01(10) 120.01(10) 120.01(10) 
Crystal system monoclinic triclinic monoclinic 
Space group P21/c P-1 P21/c 
a/Å 12.6044(13) 10.6545(9) 6.2817(6) 
b/Å 9.2309(7) 11.7338(10) 28.711(2) 
c/Å 13.0780(11) 11.7529(9) 6.3686(10) 
α/° 90 72.100(7) 90 
β/° 110.233(11) 69.880(7) 100.893(11) 
γ/° 90 63.298(9) 90 
Volume/Å3 1427.7(2) 1211.9(2) 1127.9(2) 
Z 2 2 4 
ρcalcg/cm
3 1.927 1.896 1.997 
μ/mm-1 12.783 14.267 1.713 
F(000) 844.0 709.0 696.0 
Crystal size/mm3 0.148 × 0.0978 × 0.0139 0.1149 × 0.0601 × 0.0244 0.1113 × 0.0518 × 0.0091 
Radiation CuKα (λ = 1.54184) CuKα (λ = 1.54184) MoKα (λ = 0.71073) 
2Θ range for data collection/° 7.474 to 152.726 8.148 to 146.766 5.676 to 61.746 
Index ranges -15 ≤ h ≤ 15, -11 ≤ k ≤ 10, -9 ≤ l ≤ 16 -13 ≤ h ≤ 13, -11 ≤ k ≤ 14, -9 ≤ l ≤ 14 -9 ≤ h ≤ 5, -38 ≤ k ≤ 11, -8 ≤ l ≤ 7 
Reflections collected 6650 7713 3587 
Independent reflections 2909 [Rint = 0.0651, Rsigma = 0.0759] 4615 [Rint = 0.0441, Rsigma = 0.0580] 2512 [Rint = 0.0918, Rsigma = 0.1274] 
Data/restraints/parameters 2909/0/232 4615/28/442 2512/10/173 
Goodness-of-fit on F2 1.371 1.042 1.131 
Final R indexes [I>=2σ (I)] R1 = 0.1386, wR2 = 0.3448 R1 = 0.0384, wR2 = 0.0993 R1 = 0.0910, wR2 = 0.1905 
Final R indexes [all data] R1 = 0.1674, wR2 = 0.3804 R1 = 0.0492, wR2 = 0.1092 R1 = 0.1317, wR2 = 0.2157 





Crystal data and structure refinement for crystals in chapter 6 
Identification code 6.2 6.4 
Empirical formula C26H28Cl5N3Sn1.5 C44H36Cl4.33N3Sn2 
Formula weight 737.80 997.12 
Temperature/K 120.01(10) 120.00(10) 
Crystal system triclinic orthorhombic 
Space group P-1 P212121 
a/Å 9.3940(7) 9.0744(2) 
b/Å 12.1283(9) 15.8444(3) 
c/Å 14.1617(11) 28.4493(7) 
α/° 70.950(7) 90.0 
β/° 81.926(6) 90.0 
γ/° 69.444(7) 90.0 
Volume/Å3 1427.4(2) 4089.62(17) 
Z 2 4 
ρcalcg/cm
3 1.717 1.619 
μ/mm-1 14.989 12.589 
F(000) 730.0 1977.0 
Crystal size/mm3 0.102 × 0.0505 × 0.0152 0.2275 × 0.1118 × 0.0858 
Radiation CuKα (λ = 1.54184) Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 6.606 to 153.62 6.214 to 153.646 
Index ranges -11 ≤ h ≤ 11, -15 ≤ k ≤ 15, -17 ≤ l ≤ 13 -11 ≤ h ≤ 11, -14 ≤ k ≤ 19, -32 ≤ l ≤ 35 
Reflections collected 13173 39629 
Independent reflections 5925 [Rint = 0.0649, Rsigma = 0.0644]  [Rint = 0.0661, Rsigma = 0.0451] 
Data/restraints/parameters 5925/1/326 8536/7/ 548 
Goodness-of-fit on F2 1.044 1.041 
Final R indexes [I>=2σ (I)] R1 = 0.0552, wR2 = 0.1463 R1 = 0.0416, wR2 = 0.1078 
Final R indexes [all data] R1 = 0.0609, wR2 = 0.1568 R1 = 0.0463, wR2 = 0.1125 
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